recombinant blue tongue virus vaccines and their uses

专利摘要:
RECOMBINANT VACCINES OF THE BLUE LANGUAGE VIRUS AND USES OF THE SAME. The present invention encompasses vaccines or BVT compositions. The vaccine or composition can be a vaccine or composition containing BVT antigens. The invention also encompasses recombinant vectors that encode and express BVT antigens, epitopes or immunogens that can be used to protect animals, such as sheep, cattle, or goats, against BVT.
公开号:BR112012023852B1
申请号:R112012023852-3
申请日:2011-03-11
公开日:2020-11-10
发明作者:Jean-Christophe Audonnet；Xuan Guo；Kevin Cox
申请人:Biolex Therapeutics；Merial, Inc.；
IPC主号:

专利说明:

CROSS REFERENCE TO RELATED REQUESTS
This application claims benefit from US Provisional Patent Application Serial Number 61 / 313,164, filed on March 12, 2010 and US Provisional Patent Application Serial Number 61 / 366,363 filed on July 21, 2010. FIELD OF THE INVENTION
The present invention relates to compositions to combat infection by the Blue Tongue Virus (BTV) in animals. The present invention provides pharmaceutical compositions comprising a BTV antigen, methods of vaccination against BTV, and kits for use with such methods and compositions. BACKGROUND OF THE INVENTION
Blue Tongue (BT) is a disease transmitted by arthropods, an infectious virus of ruminants. Cattle and goats can be readily infected with the causal Blue Tongue Virus (BTV), but without extensive vascular damage and, therefore, these species generally do not show marked clinical signs. In contrast, sheep disease is characterized by catarrhal inflammation of the mucous membranes of the mouth, nose and stomachs, and by inflammation of the coronary bands and hoof blades. An excoriation of the epithelium occurs and, ultimately, necrosis of the oral mucosa; the swollen and inflamed tongue and mouth may have a blue color after which the disease is called (Spreull 1905). The death rate in sheep is estimated at 1-30%.
BTV is the prototype virus of the genus Orbivirus (family Reoviridae), and is composed of at least 24 different serotypes (Wilson and Mecham, 2000). Different strains of BTV have been identified throughout the world across tropical and temperate zones. BTV infection occurred as much as 45 ° N in Europe, as much as 50 ° N in Asia and North America, and even in the South at 35 ° N. BTV is not contagious among ruminants, so the distribution of BTV is dependent on the presence of species of arthropod vectors from coides sp. (mosquito bites), with different vector species occurring in different regions of the world. Recent data suggest that the genetic deviation and founding effect contribute to the diversification of individual gene segments of BTV field strains (Bonneau, Mullens et al., 2001).
BTV infection of ruminants is transient, while infection of the Culícoides insect vector is persistent. The duration of viremia depends on the animal species and the BTV strain. It has been reported that viremia can be very transient in sheep and can last up to 41 days in individuals infected with BTV, up to 42 days in goats, and up to 100 days in cattle. Since cattle BTV infection often results in prolonged, but not permanent, viremia, cattle serve as a reservoir from which the virus can be ingested by the Culicoides vector and then transmitted to other ruminants (Anderson, Stott et al 1985; MacLachlan 1994; MacLachlan and Pearson 2004). The ecology of several species of Culicoides vectors is poorly understood and their breeding sites are largely uncharacterized and their dispersion rates unknown. Culicoides sonorensis is the main vector of BTV in North America. Culicoides female insects have become persistently infected with BTV and can transmit the virus after an extrinsic incubation period of up to 14 days (Mullens, Tabachnick et al. 1995). BTV hibernation in temperate zones can occur through vertically infected insect vectors, although recent data indicate that there is reduced expression of the external capsid genes during persistent BTV infection in larval stages of insect vectors (White, Wilson and col. 2005).
BTV virions have a diameter of ~ 69 nm with a double shell coating (capsid), which is sometimes surrounded by a "pseudo-envelope" lipoprotein derived from the cell membranes of infected cells. The BTV genome includes 10 distinct segments of double-stranded RNA that collectively encode seven structural proteins (VP1 to VP7) and four non-structural proteins (NS1, NS2, NS3 and NS3a) (Roy 1996); Nine of the genome segments are monocistronic, while 10 segments encode both NS3 and NS3A using a second inframe initiation codon. The genomic RNA is encapsulated in the icosahedral particle of virion by a double-layer protein capsid (Verwoerd, Eis et al. 1972). The icosahedral nucleus consists of two main proteins (VP3 and VP7) and three secondary proteins (VP1, VP4, VP6) and is surrounded by the outer capsid consisting of VP2 and VP5 which are, respectively, encoded by genomic segments 2 and 5 (Roy 1996). VP2 is responsible for the agglutination and entry of BTV into cells, neutralization, specificity of serotype and hemagglutination. Multimeric forms of VP2 (dimers and trimers) decorate much of the surface of a VP5 support on the outer surface of the viral particles (Hassan and Roy, 1999). VP2 varies more among the 24 BTV serotypes, and anti-VP2 antibody levels correlate with the neutralization of the virus in vitro and in vivo (Huismans and Erasmus 1981). VP5 also varies markedly between different BTV serotypes and strains (de Mattos, Mattos et al. 1994; DeMaula, Bonneau et al. 2000) and, although no specific neutralizing VP5 MAb has been identified so far, data suggest that this protein has a role in neutralizing and determining serotype through its conformational influence on VP2 (Huismans and Erasmus 1981; Roy, Urakawa et al. 1990; DeMaula et al., 2000). Purified VP2 immunosorbed with BTV anti-core serum to remove traces of VP7 provided protection against the same BTV serotype infection in sheep (Huismans, van der Walt et al. 1987). Recent results show that VP2 and NS1 express epitopes recognized by cytotoxic T lymphocytes (CTL) (Andrew, Whiteley et al. 1995), while VP7 and VP5 are unlikely to have CTL epitopes. Until now, VP3, VP4, VP6, NS2 and NS3 have not stimulated a CTL response in sheep (Lobato, Coupar et al. 1997).
Lobato and Coupar (Lobato, Coupar et al. 1997) developed expression vectors based on the vaccinia virus containing several inserts corresponding to nucleotide sequences that encode the structural proteins VP2, VP5 and VP7 of BTV for both in vivo and in vitro studies. These expression vectors were administered to rabbits and sheep to assess the immune response to ELISA and neutralizing antibody titers and the protective efficacy of the VP2 and VP5 constructs was tested in sheep. VP2, VP5 and VP2 + VP5 expressed by vaccinia virus were protective, with the most reproducible protection occurring in animals immunized with both VP2 and VP5, however, even protection with these constructs was variable and not completely effective. Efforts to develop recombinant BTV vaccine compositions can be found, for example, in US published patent application US 2007/280960. Still others have described immunological BTV compositions containing various BTV antigens produced, for example, by baculovirus (see, for example, U.S. Patent Numbers 5,833,995 and 5,690, 938).
Thus, it would be advantageous to provide improved vaccine and immunogenic compositions against BTV, and methods for producing and using such compositions, including such compositions that provide differential dragnostic methods, assays and kits.
Recently, plants have been investigated as a source for the production of therapeutic agents, such as vaccines, antibodies, and biopharmaceuticals. However, the production of vaccines, antibodies, proteins, and biopharmaceuticals from plants is far from a solution process, and there are numerous obstacles that are normally associated with such vaccine production. Limitations for successful plant vaccines include low yield of the expressed bioproduct or antigen (Chargelegue et al., Trends in Plant Science 2001, 6, 495-496), protein instability, inconsistencies in product quality (Schillberg et al., Vaccine 2005, 23, 1764-1769), and insufficient capacity to produce products of the viral type of expected size and immunogenicity (Arntzen et al., Vaccine 2005, 23, 1753-1756). In order to solve these problems, codon optimization, careful approaches to harvesting and purifying plant products, the use of plant parts, such as chloroplasts to enhance material absorption, and improved subcellular orientation are all being considered as strategies. potential (Koprowski, Vaccine 2005, 23, 1757-1763).
Considering the animals' susceptibility to BTV, a method to prevent BTV infection and protect animals is essential. Therefore, there is a need for an effective vaccine against BTV. SUMMARY OF THE INVENTION
Compositions are provided which comprise a BTV polypeptide and antigenic fragments and variants thereof. BTV antigens and fragments and variants thereof have immunogenic and protective properties. BTV antigens can be produced on a plant or algae.
Polypeptides and antigenic fragments and variants thereof can be formulated in vaccines and / or pharmaceutical compositions. Such vaccines can be used to vaccinate an animal and provide protection against at least one BTV strain.
The methods of the present invention include methods for producing antigenic polypeptides in plants or algae. The methods also include methods of use, including administering to an animal an effective amount of a polypeptide or antigenic fragment or variants thereof to produce a protective immunogenic response. After production in plants or algae, the antigenic polypeptide can be partially or substantially purified for use as a vaccine. BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description, given by way of example, but which is not intended to limit the invention to only the specific modalities described, can be better understood together with the accompanying drawings, in which:
Figure 1 represents a table that summarizes the SEQ ID
NO attributed to protein and DNA sequences.
Figure 2 represents the plasmid pCG102 encoding BTV1 VP5 (SEQ ID NO: 10), used as a positive control for the screening.
Figure 3 represents the plasmid pCGlOO encoding BTV1 VP2 (SEQ ID NO: 4), used as a positive control for the screening.
Figure 4 represents the plasmid pCGlOl that encodes BTV1 VP2 - c-myc (SEQ ID NO: 6), used as a positive control for the screening.
Figure 5 is a Western blot of CHO cell lysates that indicates the AHSV VP5 antibody 10AE12, which selectively detects the BTV1 VP5 protein expressed by pCG102 (SEQ ID NO: 10).
Figure 6 is a Western blot of CHO cell lysates that indicates the mouse anti-c-Myc antibody that selectively detects the BTV1 VP2 protein expressed by c-Myc-labeled pCGlOl (SEQ ID NO: 6), but does not detect BTV1 VP2 protein expressed by unlabeled pCGlOO (SEQ ID NO: 4).
Figures 7a and 7b are Western blots of CHO cell lysates that have been transfected with the indicated constructs. Both BTV1 VP2 L167 and L168 polyclonal antibodies selectively detected the VP2 protein (SEQ ID NO: 4) expressed in cells transfected with pCGlOO.
Figure 8 shows the sequence alignment of the polynucleotides encoding BTV VP2 and the percentage of sequence identity.
Figure 9 shows the sequence alignment of the polynucleotides encoding BTV VP5 and the percentage of sequence identity.
Figure 10 represents the identity and location of the BTV1 antigens optimized by duckweed for the four duckweed expression constructs.
Figure 11 represents the plasmid pMerDOl containing the VP2 and VP5 cytoplasmatically located one after the other.
Figure 12 represents plasmid MerD02 containing VP2 cytoplasmatically located with optimized 5'UTR and VP5 in sequence.
Figure 13 represents plasmid MerD03, VP2 cytoplasmatically located alone.
Figure 14 represents the plasmid MerD04, VP2 cytoplasmatically located with 5'UTR optimized alone.
Figure 15 represents Western blots representative of duckweed lysates expressing various MerD constructs using the VP2 antibody.
Figure 16 represents Western blots representative of duckweed lysate expressing construct MerDOl using the VP2 and VP5 antibodies.
Figure 17 represents a Western blot VP2 of lysates from duckweed expressing MerDOl, MerD02, MerD03 and Mer04.
Figure 18 represents a Western blot of VP5 monoclonal antibody clone # 10AE12 from duckweed lysates expressing MerDOl and MerD02.
Figure 19 represents a representative image used for VP2 Agilent 2100 Bioanalyzer densitometry analysis.
Figure 20 represents the average size of local reactions at the injection sites.
Figure 21 represents the rectal temperature after the first BTV vaccination.
Figure 22 represents the rectal temperature after the second BTV vaccination.
Figure 23 represents the rectal temperature after BTV challenge.
Figure 24 represents the clinical signs after BTV challenge.
Figure 25 represents the BTV1 antibody titre by seroneutralization.
Figure 26 represents the mean viremia titer measured by qRT-PCR in each treatment group.
Figure 27 shows the alignment of the BTV1 VP2 protein sequence and the percentage of sequence identity.
Figure 28 shows the protein sequence alignment of seven BTV1 VP5 and a BTV2 VP5 sequence and the percent sequence identity. DETAILED DESCRIPTION
Compositions are provided which comprise a polypeptide, antigen and BTV fragments, and variants thereof which induce an immunogenic response in an animal. Polypeptides or antigenic fragments or variants thereof are produced in a plant or algae. Polypeptides or antigenic fragments or variants can be formulated in vaccines or pharmaceutical compositions and used to induce or stimulate a protective response in an animal. In one embodiment, the polypeptide antigen is a BTV VP2 or BTV VP5 polypeptide or active fragment or variant thereof.
It is recognized that the antigenic polypeptides of the invention can be full-length polypeptides or active fragments or variants thereof. By "active fragments" or "active variants" it is understood that the fragments or variants retain the antigenic nature of the polypeptide. Thus, the present invention encompasses any BTV polypeptide, antigen, epitope, or immunogen that induces an immunogenic response in an animal. The BTV polypeptide, antigen, epitope, or immunogen can be any BTV polypeptide, antigen, epitope or immunogen, such as, but not limited to, a protein, peptide or fragment or fragment or variant thereof, which causes, induces or stimulates a response in an animal, such as a sheep, bovine, or goat.
The present invention relates to bovine, ovine, or goat vaccines or compositions that can comprise an effective amount of a recombinant BTV antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant or vehicle.
In some embodiments, vaccines still comprise adjuvants, such as oil-in-water (O / W) emulsions, described in U.S. Patent 7,371,395.
In still other modalities, adjuvants include EMULSIGEN®, Aluminum hydroxide and Saponin, CpG, or combinations thereof.
In some embodiments, the response in the animal is a protective immune response.
"Animal" means mammals, birds and the like. Animal or host includes mammals and humans. The animal can be selected from the group consisting of equines (for example, horse), canines (for example, dogs, wolves, foxes, coyotes, jackals), felines (for example, lions, tigers, domestic cats, wild cats , other big cats and other felines, including leopards and lynx), sheep (eg sheep), cattle (eg cattle), pigs (eg pig), goats (eg goat), birds (eg , hen, duck, goose, turkey, quail, pheasant, parrot, chaffinch, falcon, crow, ostrich, emu and cassowary), primates (for example, prosimius, tarsier, monkey, gibbon, ape) and fish. The term "animal" also includes an individual animal at all stages of development, including embryonic and fetal stages.
The term "plants", as used herein, includes both dicot plants (dicot) and monocot plants (monocot). Dicotyledonous plants include, but are not limited to, vegetables such as peas, alfalfa, and soybeans, carrots, celery, tomatoes, potatoes, tobacco, pepper, rapeseed oil, beets, kale, cauliflower, broccoli, lettuce, peanuts , and the like. Monocotyledonous plants include, but are not limited to, cereals, such as wheat, barley, sorghum and millet, rye, triticale, maize, rice or oats, sugar cane, duckweed, grasses, and the like. The term "plant" also includes non-flowering plants including, but not limited to, ferns, mackerel, mosses, liverworts, anthocera, algae. The term "algae" and "alga", as used herein, includes any strain of alga capable of producing a polypeptide or fragment or variant thereof. Algae can include red, brown, and green algae, gametophytes, and the like. Algae can be microalgae. The microalgae can be Thraustochytriaceae, for example, Schizochytrium, Thraustochytrium, Labyrinthuloides and Japonochytrium.
Unless otherwise explained, all technical and scientific terms used herein have the same meaning as normally understood by one skilled in the art to which this description belongs. The singular terms "um", "uma", and "o / a" include plural references unless the context clearly indicates otherwise. Likewise, the word "or" is meant to include "and" unless the context clearly indicates otherwise.
It is noted that in this description and, particularly in the claims and / or paragraphs, terms such as "comprises", "understood", "comprising" and the like may have the meaning ascribed to them in US Patent Law; , may mean "includes", "included", "including", and the like, and that terms such as "consisting essentially of" and "consisting essentially of" have the meaning ascribed to them in US Patent Law, for example, they allow elements not explicitly recited, but exclude elements that are found in the state of the art or that affect a basic or new feature of the invention.
The antigenic polypeptides of the invention are capable of protecting against BTV. That is, they are able to stimulate an immune response in an animal. By "antigen" or "immunogen" is meant a substance that induces a specific immune response in a host animal. The antigen can comprise an entire organism, dead, attenuated or alive; a subunit or portion of an organism; a recombinant vector containing an insert with immunogenic properties; a piece or fragment of DNA capable of inducing an immune response against presentation to a host animal; a polypeptide, an epitope, a hapten, or any combination thereof. Alternatively, the immunogen or antigen may comprise a toxin or antitoxin. The term "protein, polypeptide, or immunogenic peptide" as used herein includes polypeptides that are immunologically active in the sense that, once administered to the host, it is capable of evoking a humoral and / or cellular immune response directed against the protein. Preferably, the protein fragment is such that it has substantially the same immunological activity as the total protein. Thus, a protein fragment according to the present invention comprises or consists essentially of, or consists of at least one epitope or antigenic determinant. An "immunogenic" protein or polypeptide, as used herein, includes the full length sequence of the protein, analogs thereof, or immunogenic fragments thereof. By "immunogenic fragment" is meant a fragment of a protein that includes one or more epitopes and thus induces the immune response described above. Such fragments can be identified using any number of epitope mapping techniques, well known in the art. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) .For example, linear epitopes can be determined, for example, by concurrently synthesizing a large number of peptides on solid supports. , the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies, while the peptides are still attached to the supports, such techniques are known in the art and described in, for example, US Patent No. 4,708,871; Geysen et al. , 1984; Geysen et al., 1986. Likewise, conformational epitopes are readily identified by determining the spatial conformation of amino acids, such as, for example, by X-ray crystallography and two-dimensional nuclear magnetic resonance. See, for example, Epitope Mapping Protocols, supra.
As discussed, the invention encompasses active fragments and variants of the antigenic polypeptide. Thus, the term "protein, polypeptide, or immunogenic peptide" further encompasses deletions, additions and substitutions for the sequence, as well as the polypeptide functions to produce an immune response, as defined herein. The term "conservative variation" denotes the replacement of an amino acid residue by another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence in such a way that the encoded amino acid residue is not altered, that is, another residue biologically similar. In this regard, particularly preferred substitutions will generally be conservative in nature, that is, those substitutions that occur within a family of amino acids. For example, amino acids are generally divided into four families: (1) acids - aspartate and glutamate; (2) basic - lysine, arginine, histidine; (3) supports - alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) unloaded polar - glycine, asparagine, glutamine, cistern, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified as aromatic amino acids. Examples of conservative variations include replacing a hydrophobic residue, such as isoleucine, valine, leucine or methionine with another hydrophobic residue, or replacing a polar residue with another polar residue, such as replacing arginine with lysine, glutamic acid with aspartic acid, or asparagine glutamine, and the like; or a similar conservative substitution of an amino acid with a structurally related amino acid, which will not have an important effect on biological activity. Proteins having substantially the same amino acid sequence as the reference molecule, but having small amino acid substitutions that do not substantially affect the immunogenicity of the protein are, therefore, within the definition of the reference polypeptide. All polypeptides produced by these modifications are included here. The term "conservative variation" also includes the use of a substituted amino acid in place of an amino acid of unsubstituted origin, provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.
The term "epitope" refers to the site on an antigen or hapten, to which specific B cells and / or T cells respond. The term is also used interchangeably with "antigenic determinant" or "antigenic determinant site". Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.
An "immune response" to a composition or vaccine is the development in the host of a cellular and / or antibody-mediated immune response to a composition or vaccine of interest. Generally, an "immune response" includes, but is not limited to, one or more of the following effects: the production of antibodies, B cells, helper T cells, and / or cytotoxic T cells, specifically directed to an antigen or antigens included in the composition or vaccine of interest. Preferably, the host will exhibit either a therapeutic or protective immune response, such that resistance to the new infection will be intensified and / or the clinical severity of the disease reduced. Such protection will be demonstrated either by a reduction or lack of symptoms normally present by an infected host, a faster recovery time and / or a reduced viral titer in the infected host.
Synthetic antigens are also included in the definition, for example, polyepitopes, flanking epitopes, and other recombinants or synthetically derived antigens. See, for example, Bergmann et al., 1993; Bergmann et al., 1996; Suhrbier, 1997; Gardner et al., 1998. Immunogenic fragments, for the purposes of the present invention, will normally include at least about 3 amino acids, at least about 5 amino acids, at least about 10-15 amino acids, or about 15-25 amino acids or more amino acids in the molecule. There is no critical upper limit to the length of the fragment, which can comprise almost the total length of the protein sequence, or even a fusion protein that comprises at least one epitope of the protein.
Accordingly, a minimal structure of a polynucleotide that expresses an epitope is one that comprises or consists essentially of, or consists of, nucleotides that encode an epitope or antigenic determinant of a BTV polypeptide. A polynucleotide encoding a fragment of a BTV polypeptide may comprise or consist essentially of, or consist of, a minimum of 15 nucleotides, about 30-45 nucleotides, about 45-75, or at least 57, 87 or 150 consecutive nucleotides or contiguous to the sequence encoding the polypeptide. Epitope determination procedures, such as generation of overlapping peptide libraries (Hemmer et al., 1998), Pepscan (Geysen et al., 1984; Geysen et al., 1985; Van der Zee R. et al., 1989; Geysen , 1990; Multipin. RTM. Peptide Synthesis Kits by Chiron) and algorithms (De Groot et al., 1999; PCT / US2004 / 022605) can be used in the practice of the present invention. The term "nucleic acid" or "polynucleotide" refers to RNA or DNA, which is linear or branched, single or double stranded, or a hybrid thereof. The term also comprises RNA / DNA hybrids. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, DNA isolated from any sequence, RNA isolated from any sequence nucleic acid probes and primers. A polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracil, other sugars and linker groups, such as fluoribose and thiolate, and nucleotide branches. The nucleotide sequence can be further modified after polymerization, such as by conjugation, with a labeling component.
Other types of modifications included in this definition are caps, replacing one or more of the naturally occurring nucleotides with an analog, and introducing means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides or solid support. Polynucleotides can be obtained by chemical synthesis or derived from a microorganism.
The term "gene" is used widely to refer to any segment of polynucleotide associated with a biological function. Thus, genes include introns and exons as in the genomic sequence, or just the coding sequences, as in cDNAs and / or the regulatory sequences necessary for their expression. For example, a gene also refers to a fragment of nucleic acid that expresses functional mRNA or RNA, or encodes a specific protein, and that includes regulatory sequences.
The invention further comprises a filament complementary to a polynucleotide encoding a BTV antigen, epitope or immunogen. The complementary filament can be polymeric and of any length, and can contain deoxyribonucleotides, ribonucleotides, and the like in any combination.
The terms "protein", "peptide", "polypeptide" and "polypeptide fragment" are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer can be linear or branched, can comprise modified amino acids or amino acid analogs, and can be disrupted by different chemical portions of amino acids. The terms also cover an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a bioactive or labeled component.
An "isolated" biological component (such as a nucleic acid or protein or organelle) refers to a component that has been substantially separated or purified from other biological components in the organism's cell where the component occurs naturally, for example, other DNA and Chromosomal and extrachromosomal RNA, proteins and organelles. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also covers nucleic acids and proteins prepared by recombinant technology, as well as chemical synthesis.
The term "purified", as used herein, does not require absolute purity; but rather, it is understood as a relative term. Thus, for example, a purified polypeptide preparation is one in which the polypeptide is more enriched than the polypeptide that is in its natural environment. That is, the polypeptide is separated from cellular components. By "substantially purified" is meant that such polypeptide represents several modalities, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98%, or more of the components cell phones or materials have been removed. Likewise, the polypeptide can be partially purified. By "partially purified" it is intended that less than 60% of the cellular components or materials are removed. The same applies to polynucleotides. The polypeptides described herein can be purified by any means known in the art.
As noted above, antigenic polypeptides or fragments or variants thereof are BTV antigenic polypeptides that are produced in plants or algae. Fragments and variants of the described polynucleotides and polypeptides encoded therewith are also encompassed by the present invention. By "fragment" is meant a portion of the polynucleotide or a portion of the antigenic amino acid sequence encoded therewith. Fragments of a polynucleotide can encode protein fragments that retain the biological activity of the native protein and, consequently, possess immunogenic activity as referred to in this document. Fragments of the polypeptide sequence retain the ability to induce a protective immune response in an animal.
By "variants" is meant to mean substantially similar sequences. For polynucleotides, a variant comprises a deletion and / or addition of one or more nucleotides at one or more sites within the native polynucleotide and / or a replacement of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a "native" polynucleotide or polypeptide comprises a naturally occurring nucleotide sequence or an amino acid sequence, respectively. Variants of a particular polynucleotide of the invention (i.e., the reference polynucleotide), can also be evaluated by comparing the percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide. "Variant" protein is meant to mean a protein derived from the native protein by deleting or adding one or more amino acids at one or more sites on the native protein and / or replacing one or more amino acids at one or more sites on the native protein. Variant proteins encompassed by the present invention are biologically active, that is, they have the ability to induce an immune response.
In one aspect, the present invention provides ovine, bovine or caprine BTV polypeptides. In another aspect, the present invention provides a polypeptide having a sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 , 23, 24, or 25, and variant or fragment thereof.
In addition, ovine, bovine, or goat BTV polypeptide homologues are intended to be within the scope of the present invention. As used herein, the term "homologues" includes orthologists, analogs and analogues. The term "analogues" refers to two polynucleotides or polypeptides that function the same or similar, but that have evolved separately in unrelated organisms. The term "orthologists" refers to two polynucleotides or polypeptides of different species, but which evolved from a common ancestral gene through speciation. Typically, orthologists encode polypeptides having the same or similar functions. The term "parallels" refers to two polynucleotides or polypeptides that are related by duplication within a genome. Parallels generally have different functions, but these functions can be related. Analogs, orthologs, and parallels of a wild-type BTV polypeptide may differ from the wild-type BTV polypeptide by post-translational modifications, differences in amino acid sequences, or both. In particular, homologues of the invention will, in general, exhibit at least 80-85%, 85-90%, 90-95%, or 95%, 96%, 97%, 98%, 99% sequence identity with all or part of the wild-type BTV polypeptide or polynucleotide sequences, and will exhibit a similar function. Variants include allelic variants. The term "allelic variant" refers to a polynucleotide or polypeptide that contains polymorphisms that lead to changes in the amino acid sequences of a protein and that exist within a natural population (for example, a species or variety of viruses). Such natural allelic variations can typically result in 1-5% variance in a polynucleotide or polypeptide. Allelic variants can be identified by sequencing the nucleic acid sequence of interest in a variety of different species, which can be easily performed by using hybridization probes to identify the same genetic locus of the gene in these species. Any and all of these variations of nucleic acid and resulting polymorphisms or amino acid variations that are the result of natural allelic variation and that do not alter the functional activity of the gene of interest, are intended to be within the scope of the invention.
As used herein, the term "derivative" or "variant" refers to a polypeptide, or a nucleic acid that encodes a polypeptide, which has one or more conservative amino acid variations or other minor modifications, such as (1) the polypeptide correspondent has substantially equivalent function when compared to the wild type polypeptide or (2) an antibody raised against the polypeptide is immunoreactive with the wild type polypeptide. These variants or derivatives include polypeptides having minor modifications to the primary amino acid sequences of BTV polypeptides that can result in peptides that have substantially equivalent activity compared to the unmodified counterpart polypeptide. Such changes may be deliberate, as per site-directed mutagens, or they may be spontaneous. The term "variant" further encompasses deletions, additions and substitutions for the sequence, as long as the polypeptide functions produce an immune response, as defined herein.
The term "conservative variation" denotes the replacement of an amino acid residue with another biologically similar residue, or the replacement of a nucleotide in a nucleic acid sequence in such a way that the encoded amino acid residue does not change or is another biologically residue. similar. In this regard, particularly preferred substitutions will generally be conservative in nature, as described above.
The polynucleotides of the present description include sequences that are degenerated as a result of the genetic code, for example, the use of codons optimized for a specific host. As used here, "optimized" refers to a polynucleotide that is genetically modified to enhance its expression in a given species. To provide optimized polynucleotides that encode BTV polypeptides, the DNA sequence of the BTV protein gene can be modified to 1) comprise the codons preferred by genes highly expressed in a particular species; 2) comprise an A T T or G + C content in the nucleotide-based composition to that substantially found in said species; 3) form an initiation sequence for said species; or 4) eliminate sequences that cause destabilization, inappropriate polyadenylation, degradation and termination of RNA, or that form secondary structure clamps or RNA splicing sites. The increased expression of BTV protein in these species can be achieved through the use of the distribution frequency of the use of the codon in species of eukaryotes and prokaryotes, or in a particular species. The term "preferred codon usage frequency" refers to the preference displayed by a specific host cell for using nucleotide codons to specify a particular amino acid. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the description, as long as the amino acid sequence of the BTV polypeptide encoded by the nucleotide sequence is functionally unchanged.
The sequence identity between the two amino acid sequences can be established by the paired blast NCBI (National Center for Biotechnology Information) and the blosum62 matrix, using standard parameters (see, for example, the BLAST or BLASTX algorithm available on the "National" server Center for Biotechnology Information "(NCBI, Bethesda, Md., USA), as well as in Altschul et al .; and, thus, this document refers to the use of the algorithm or BLAST or BLASTX and the BLOSUM62 matrix by the term" blasts " ).
The "identity" with respect to the sequences can refer to the number of positions with identical nucleotides or amino acids, divided by the number of nucleotides or amino acids in the shortest of the two sequences where the alignment of the two sequences can be determined according to the Wilbur and Lipman's algorithm (Wilbur and Lipman), for example, using a window size of 20 nucleotides, a word length of 4 nucleotides, and a gap penalty of 4, and analysis with the aid of computer and data interpretation of the sequence, including alignment, can be conveniently performed using commercially available programs (for example, Intelligenetics ™ Suite, Intelligenetics Inc. CA). When RNA sequences are said to be similar, or have a degree of sequence identity or homology to DNA sequences, thymidine (T) in the DNA sequence is considered to be equal to uracil (U) in the RNA sequence. Thus, the RNA sequences are within the scope of the invention, and can be derived from the DNA sequences, by thymidine (T) in the DNA sequence being considered equal to uracil (U), in the RNA sequences.
The sequence identity or sequence similarity of two amino acid sequences, or the sequence identity between two nucleotide sequences can be determined using the Vector NTI program package (Invitrogen, 1600 Faraday Ave., Carlsbad, CA).
The following documents provide algorithms for comparing the relative identity or homology of strings, and in addition or alternatively with respect to the precedent, the teachings in these references can be used to determine homology or percent identity: Needleman SB and Wunsch CD; Smith TF and Waterman MS; Smith TF, Waterman MS and Sadler JR; Feng DF and Dolittle RF; Higgins DG and Sharp PM; Thompson JD, Higgins DG and Gibson TJ; and, Devereux J, Haeberlie P and Smithies O. And, without undue experimentation, the person skilled in the art can consult with many other programs or references to determine the percentage homology.
Hybridization reactions can be carried out under conditions of different "stringencies". Conditions that increase the stringency of a hybridization reaction are well known. See, for example, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al., 1989).
The invention also encompasses BTV polynucleotides contained in a vector molecule or an expression vector and operationally linked to a promoter element and, optionally, to an enhancer.
A "vector" refers to a recombinant DNA or RNA plasmid or virus that comprises a heterologous polynucleotide to be delivered to a target cell, either in vitro or in vivo. The heterologous polynucleotide can comprise a sequence of interest for prevention or therapy purposes and can optionally be in the form of an expression cassette. As used herein, a vector does not need to be capable of replication in the final individual target cell. The term includes cloning vectors and viral vectors.
The term "recombinant" means a polynucleotide of semi-synthetic or synthetic origin that either does not occur in nature or is linked to another polynucleotide in an arrangement not found in nature.
"Heterologist" means derived from an entity genetically distinct from the rest of the entity to which it is being compared. For example, a polynucleotide can be placed using genetic engineering techniques on a plasmid or vector derived from a different source, and is a heterologous polynucleotide. A promoter removed from its native coding sequence and operably linked to a coding sequence other than the native sequence is a heterologous promoter.
The present invention relates to vaccines or pharmaceutical or immunological compositions of sheep, cattle and goats that can comprise an effective amount of recombinant BTV antigens and a pharmaceutically or veterinarily acceptable carrier, excipient or vehicle.
The subject described in this document is directed, in part, to compositions and methods related to the BTV antigen prepared in an algae or plant expression system that was highly immunogenic and protected animals against the challenge of BTV strains. Compositions
The present invention relates to a BTV vaccine or composition that can comprise an effective amount of a recombinant BTV antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle. In one embodiment, the recombinant BTV antigen is expressed on a plant or algae.
In one embodiment, the subject described here is directed to a composition that comprises a BTV antigen produced by a duckweed expression system and duckweed plant material, including the Lema genus, and a carrier , pharmaceutically or veterinarily acceptable excipient or vehicle.
In one embodiment, the recombinant BTV antigen is expressed in algae. In yet another modality, algae are selected from Schizochytrium. In one embodiment, the recombinant BTV antigen can be expressed in a Schizochytrium protein expression system, as described, for example, in US Patent No. 7,001,772 and in the publication of US Patent Application No. 2008/0022422.
In one embodiment, the subject described here is directed to a protein produced by a plant or algae expression system that comprises a BTV antigen and plant material or algae.
In one embodiment, the subject described here is directed at a vaccine or composition that comprises a BTV antigen produced by a duckweed expression system and duckweed plant material.
In one embodiment, the subject described here is aimed at a plant or a stably transformed plant culture that expresses a BTV antigen in which the plant or plant culture is duckweed.
The present invention encompasses any BTV polypeptide, antigen, epitope, or immunogen that elicits an immunogenic response in an animal, such as an ovine, bovine, or goat. The BTV polypeptide, antigen, epitope, or immunogen can be any BTV polypeptide, antigen, epitope, or immunogen, such as, but not limited to, a protein, peptide, or fragment thereof, which causes, induces, or stimulates a response in an animal, such as a sheep, bovine, or goat.
In one embodiment, wherein the BTV immunological composition or vaccine is an recombinant immunological composition or vaccine, the composition or vaccine that comprises a recombinant vector and an acceptable pharmaceutical or veterinary excipient, carrier or vehicle; the recombinant vector is the plant expression vector that can comprise a polynucleotide that encodes a polypeptide, antigen, epitope, or immunogen. The BTV polypeptide, antigen, epitope or immunogen can be VP1, VP2, VP3, VP4, VP5, NS1, VP7, NS2, VP6, NS3, NS3a, or any fragment thereof.
In another embodiment, the BTV polypeptide, antigen, epitope, or immunogen can be derived from an ovine, bovine, or goat infected with a BTV strain. In one embodiment, the BTV antigen, epitope or immunogen is an RNA polymerase (VP1), an external capsid protein (VP2, VP5), an internal capsid protein (VP3), a capping enzyme (VP4), a protein tubule formation (NS1), an outer core surface protein (VP7), a matrix protein (NS2), a helicase (VP6) and glycoproteins (NS3 and NS3a). Table 1 (modified from Wilson and Mecham 2000) below summarizes the BTV genes and their protein functions. Table 1. Blue Tongue Virus genes and proteins encoded with the location, properties and function of 5 proteins



In an embodiment where the BTV immunological composition or vaccine is an recombinant immunological composition or vaccine, the composition or vaccine that comprises a recombinant vector and an acceptable pharmaceutical or veterinary excipient, carrier or vehicle; the recombinant vector is a plant expression vector that can comprise a polynucleotide that encodes a BTV polypeptide, antigen, epitope, or immunogen. The BTV polypeptide, antigen, epitope or immunogen can be an external BTV capsid polypeptide (VP2, VP5), core or subnucleus capsid protein (VI, VP3, or VP4), or other polypeptides, such as NS1, NS2 , NS3, VP6, or VP7.
In one embodiment, the BTV antigen, epitope or immunogen is VP2 or VP5. In another modality, VP2 can be modified in such a way that it is located in the cytoplasm when expressed in duckweed. In another modality, VP2 can have a 5'UTR optimized for duckweed expression.
In yet another embodiment, the BTV antigen can be derived from BTV1. In one embodiment, the BTV1 sequences are optimized to express in duckweed.
In another embodiment, the BTV antigen can be VP2 or VP5. In yet another embodiment, the BTV antigen can be BTV serotype VP2 or VP5 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24. In another embodiment, VP2 or VP5 is isolated from the French isolate.
The present invention relates to a BTV composition or vaccine that can comprise an effective amount of a recombinant BTV antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle. In one embodiment, the BTV antigen can be BTV VP2 or VP5.
In another embodiment, the recombinant BTV antigen is expressed on a plant or algae. In yet another modality, the plant is a duckweed plant, including a Lemna plant. In yet another modality, the plant is Lemna minor. In one embodiment, the recombinant BTV antigen can be expressed in a proprietary Lemna minor protein expression system, advantageously the LEX system from BiolexSM.
In another embodiment, the pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle may be a water-in-oil emulsion. In yet another embodiment, the water-in-oil emulsion can be a triple water / oil / water (W / O / W) emulsion. In yet another modality, adjuvants include EMULSIGEN®, Aluminum Hydroxide and Saponin, CpG, or combinations thereof.
The invention also encompasses BTV polynucleotides contained in a vector molecule or an expression vector and operationally linked to a promoter element and, optionally, to an enhancer.
In one aspect, the present invention provides BTV polypeptides having a sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25, and variant or fragment thereof.
In another aspect, the present invention provides a polypeptide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to an antigenic polypeptide of the invention, particularly polypeptides having a sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 , 20, 21, 22, 23, 24, or 25.
In yet another aspect, the present invention provides fragments and variants of the BTV polypeptides identified above (SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24 or 25), which can be readily prepared by one skilled in the art using well-known molecular biology techniques.
The variants are homologous polypeptides having an amino acid sequence of at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence as established in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25.
An immunogenic fragment of a BTV polypeptide includes at least 8, 10, 15, or 20 consecutive amino acids, at least 21 amino acids, at least 23 amino acids, at least 25 amino acids, or at least 30 amino acids of a BTV polypeptide having a sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, or variants thereof. In another embodiment, a fragment of a BTV polypeptide includes a specific antigenic epitope found on a full-length BTV polypeptide.
In another aspect, the present invention provides a polynucleotide encoding a BTV polypeptide, such as a polynucleotide encoding a polypeptide having a sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25. In yet another aspect, the present invention provides a polynucleotide that encodes a polypeptide having at least 70%, at least 75%, at least at least 80%, at least 85%, at least 90%, at least 95%, 96%, 97%, 98% or 99% sequence identity to a polypeptide having a sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25, or a conservative variant, an allelic variant, a homologous or immunogenic fragment that comprises at least eight, or at least ten consecutive amino acids from one of these polypeptides, or a combination of these polypeptides.
In another aspect, the present invention provides a polynucleotide having a nucleotide sequence as shown in SEQ ID NO: 1, 2, 3, 5, 6, 7, 8, or 9, or a variant thereof. In yet another aspect, the present invention provides a polynucleotide having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 95%, 96%, 97%, 98% or 99% sequence identity to one of a polynucleotide having a sequence as shown in SEQ ID NO: 1, 2, 3, 5, 6, 7, 8 or 9, or a variant thereof.
The polynucleotides of the invention can comprise additional sequences, such as additional coding sequences within the same transcription unit, controlling elements such as promoters, ribosome binding sites, 5 'UTR, 3'UTR, transcription terminators, polyadenylation sites, additional transcription units under the control of the same or a different promoter, sequences that allow cloning, expression, homologous recombination, and the transformation of a host cell, and any construct as may be desirable to provide embodiments of this invention.
The elements for the expression of a BTV polypeptide, antigen, epitope or immunogen are advantageously present in a vector of the invention. In the minimum form, this comprises, essentially consists of, or consists of an initiation codon (ATG), a stop codon and a promoter, and also optionally a polyadenylation sequence for certain vectors, such as plasmids and certain viral vectors, for example example, viral vectors other than poxvirus. When the polynucleotide encodes a polyprotein fragment, for example, a BTV peptide, advantageously, in the vector, an ATG is placed 5 'from the reading frame and a stop codon is placed 3'. Other elements to control expression may be present, such as enhancer sequences, stabilization sequences, such as introns and signal sequences that allow for protein secretion.
The present invention also relates to preparations comprising vectors, such as expression vectors, for example, therapeutic compositions. The preparations can comprise one or more vectors, for example, expression vectors, such as in vivo expression vectors, which comprise and express one or more BTV polypeptides, antigens, epitopes or immunogens. In one embodiment, the vector contains and expresses a polynucleotide that comprises, essentially consists of, or consists of a polynucleotide that encodes (and, advantageously expresses) a BTV antigen, epitope, or immunogen, in a pharmaceutically, carrier or excipient, or vehicle veterinarily acceptable. Thus, according to an embodiment of the invention, the other vector or vectors in the preparation comprise, essentially consist of, or consist of a polynucleotide that encodes, and under appropriate circumstances the vector expresses one or more other proteins of a polypeptide, antigen, epitope or BTV immunogen, or a fragment thereof.
According to another embodiment, the vector or vectors in the preparation comprise, or essentially consist of, or consist of polynucleotides that encode one or more proteins or fragments thereof of a BTV polypeptide, antigen, epitope or immunogen, the vector or vectors that express polynucleotides. In another embodiment, the preparation comprises one, two or more vectors comprising the polynucleotides which encode and express, advantageously in vivo, a polypeptide, antigen, fusion protein, or a BTV epitope thereof. The invention is also directed to mixtures of vectors that comprise polynucleotides that encode and express different BTV polypeptides, antigens, epitopes or immunogens, for example, a BTV polypeptide, antigen, epitope or immunogen from different animal species, such as , but not limited to, sheep, cattle, or goats.
According to a further embodiment of the invention, the expression vector is a plasmid vector or a DNA plasmid vector, in particular an in vivo expression vector. In a specific, non-limiting example, plasmid pVR1020 or 1012 (VICAL Inc., Luke et al., 1997; Hartikka et al., 1996, see, for example, US Patent Nos. 5,846,946 and 6,451,769) can be used as a vector for the insertion of a polynucleotide sequence. The plasmid pVR1020 is derived from pVR1012 and contains the human tPA signal sequence. In one embodiment, the human tPA signal comprises from amino acid M (1) to amino acid S (23) of the sequence that has the Genbank accession number HUMTPA14. In another specific, non-limiting example, the plasmid used as a vector for the insertion of a polynucleotide sequence may contain the IGF1 equine signal peptide sequence from amino acid M (24) to amino acid A (48) of the sequence it has Genbank accession number U28070. Additional information on DNA plasmids that can be consulted or used in practice is found, for example, in US Patent Nos. 6,852,705; 6,818,628; 6,586,412; 6,576,243; 6,558,674; 6,464,984; 6,451,770; 6,376,473 and 6,221,362.
The term plasmid encompasses any DNA transcription unit that comprises a polynucleotide according to the invention and the elements necessary for its expression in vivo in a cell or cells of the desired or target host; and, in this regard, it is noted that a circular, supercoiled or non-supercoiled plasmid, as well as a linear shape, is intended to be within the scope of the invention.
Each plasmid essentially comprises or consists of, in addition to the polynucleotide encoding a BTV antigen, epitope or immunogen, optionally fused to a heterologous peptide sequence, variant, analogue or fragment, operably linked to a promoter or under the control of a promoter or dependent on a promoter. In general, it is advantageous to employ a strong functional promoter in eukaryotic cells. The strong promoter can be, but is not limited to, the immediate early promoter of human or murine cytomegalovirus (CMV-IE), or optionally have another source such as rat or guinea pig, the Super promoter (Ni, M. et al. , Plant J. 7, 661-676, 1995.). The CMV-IE promoter may comprise the current promoter part, which may or may not be associated with the enhancer part. Reference can be made to EP-A-260 148, EP-A-323 597, US Patent Nos. 5,168,062, 5,385,839, and 4,968,615, as well as PCT Application No. W087 / 03905. The CMV-IE promoter is advantageously a human CMV-IE (Boshart et al., 1985) or murine CMV-IE.
More generally, the promoter has a viral origin, a plant, or a cellular origin. A strong viral promoter other than CMV-IE that can be usefully employed in the practice of the present invention is the SV40 virus early / late promoter or the Rous sarcoma virus LTR promoter. A strong cellular promoter that can be usefully used in the practice of the present invention is the promoter of a cytoskeleton gene, such as, for example, the desmin promoter (Kwissa et al., 2000), or the actin promoter ( Miyazaki et al., 1989).
Any of the constitutive, adjustable or stimulus-dependent promoters can be used. For example, constitutive promoters can include the promoter manopine synthase from Agrobacterium tumefaciens. Alternatively, it may be advantageous to use heat shock gene promoters, dry inducible gene promoters, pathogen-inducible gene promoters, wound-inducible gene promoters, and light / dark inducible gene promoters. It may be useful to use promoters that are controlled by plant growth regulators, such as abscissic acid, auxins, cytokinins, and gibberellic acid. Promoters can also be chosen from those that provide tissue-specific expression (for example, root, leaf and specific floral promoters).
Plasmids can comprise other expression control elements. It is particularly advantageous to incorporate stabilizing sequences, for example, intron sequences, for example, corn alcohol dehydrogenase intron (Callis et al. Genes & Dev. 1 (10): 1183-1200, December 1987), the first intron in hCMV-IE (PCT Application No. WO 1989/01036), the intron II of the rabbit β-globin gene (van Ooyen et al., 1979). In another embodiment, the plasmids can comprise 3'UTR. The 3 'UTR can be, but is not limited to, nopaline synthase (Nos) 3'UTR of Agrobacterium (Nopaline synthase: transcript mapping and DNA sequence. Depicker, A. et al. J. Mol. Appl. Genet., 1982; Bevan, NAR, 1984, 12 (22): 8711-8721).
As with the polyadenylation signal (polyA) for plasmids and viral vectors other than poxvirus, use may be made more of the bovine growth hormone (bGH) gene poly (A) signal (see, US 5, 122,458 ), or the poll signal (A) of the rabbit β-globin gene or the poll signal (A) of the SV40 virus.
A "host cell" refers to a prokaryotic or eukaryotic cell that has been genetically altered, or is capable of being genetically altered by the administration of an exogenous polynucleotide, such as a plasmid or recombinant vector. When referring to genetically altered cells, the term refers to both the originally altered cell and its progeny.
In one embodiment, the recombinant BTV antigen is expressed on a transgenic plant or alga. In another embodiment, the transgenic plant is a Lemna plant. In yet another modality, the transgenic plant is Lemna minor (duckweed). In yet another embodiment, the recombinant BTV antigen can be expressed in the Lemna minor protein expression system (duckweed), Biolex's LEXSM system. Details of the Lernna minor protein expression system (duckweed) can be found, for example, in US Patent Nos. 6,815,184, 7,022,309, 7,160,717, 7,176,024, 6,040,498 and 7,161,064. In yet another modality, the transgenic alga is Schizochytrium. Details of the algae protein expression system can be found, for example, in US 7,001,772, U.S. 2008/0022422. The BTV antigen in the embodiments can be any polypeptide described herein, or a polypeptide encoded by any polynucleotide described herein.
Methods for Expressing BTV Polypeptides in Duckweed or Microalgae
Thus, in some embodiments of the invention, BTV antigenic polypeptides, or fragments or variants thereof, are expressed in duckweed or microalgae. These methods include the use of expression cassettes that are introduced into a duckweed or microalgae plant using any suitable transformation method known in the art. Polynucleotides within these expression cassettes can be modified for enhanced expression of BTV antigenic polypeptide, or fragment or variant thereof, in duckweed or microalgae, as follows.
Cassettes for Expressing Duckweed or Microalgae of BTV Antigenic Polypeptides
Duckweed or transgenic microalgae expressing a BTV polypeptide, or fragment or variant thereof, is obtained by transforming duckweed or microalgae with an expression cassette comprising a polynucleotide encoding the BTV antigenic polypeptide , or fragment or variant thereof. In this way, a polynucleotide that encodes the BTV polypeptide of interest, or fragment or variant thereof, is constructed within an expression cassette and introduced into a duckweed plant or microalgae culture by any method of transformation suitable known in the art.
In some embodiments, the duckweed or microalgae plant that is transformed with an expression cassette comprising a polynucleotide encoding the BTV polypeptide of interest, or fragment or variant thereof, has also been transformed with an expression cassette that provides the expression of another heterologous polypeptide of interest, for example, another BTV polypeptide, fragment, or variant thereof. The expression cassette providing the expression of another heterologous polypeptide of interest can be supplied in the same polynucleotide (for example, in the same transformation vector) for introduction into a duckweed or microalgae plant, or in a different polynucleotide (for example, different transformation vectors) for introduction into the duckweed or microalgae plant at the same time or at different times, by the same or different methods of introduction, for example, by the same or different transformation methods.
The expression cassettes for use in the transformation of duckweed or microalgae comprise expression control elements that comprise at least one transcriptional initiation region (for example, a promoter) operably linked to the polynucleotide of interest, that is, a polynucleotide that encodes a BTV polypeptide, fragment, or variant thereof. "Operationally linked", as used herein in reference to nucleotide sequences refers to several nucleotide sequences that are placed in functional relationship with each other. Generally, the sequences of operationally linked DNA are contiguous and, when necessary, join two protein coding regions in the reading frame. Such an expression cassette is provided with a plurality of restriction sites for insertion of the polynucleotide or polynucleotides of interest (for example, one polynucleotide of interest, two polynucleotides of interest, etc.) to be under transcriptional regulation of the promoter and other control elements of expression. In particular embodiments of the present invention, the polynucleotide to be transferred contains two or more expression cassettes, each of which contains at least one polynucleotide of interest.
By "expression control element" is meant a regulatory region of DNA, normally constituted by a TATA box, capable of directing RNA polymerase II, or in some modalities, RNA polymerase III, to initiate RNA synthesis at the initiation site of appropriate transcription for a particular coding sequence. An expression control element may additionally comprise other recognition sequences generally positioned upstream or 5 'from the TATA box, which influences (for example, intensifies) the rate of transcription initiation. In addition, an expression control element may additionally comprise sequences generally positioned downstream or 3 'from the TATA box, which influences (for example, enhances) the rate of transcription initiation.
The transcriptional initiation region (for example, a promoter) can be native or homologous or exotic or heterologous to the duckweed or microalgae host, or it can be the natural sequence or a synthetic sequence. Exotic, it is intended that the transcriptional initiation region is not found in the host of wild duckweed or microalgae in which the transcriptional initiation region is introduced. By "functional promoter" is meant the promoter, when operationally linked to a sequence encoding a BTV polypeptide of interest, or fragment or variant thereof, capable of directing the expression (i.e., transcription and translation) of the polypeptide, fragment, or coded variant. Promoters can be selected based on the desired outcome. Thus, the expression cassettes of the present invention can comprise constitutive, inducible, tissue-preferred promoters, or other promoters for duckweed expression.
Any suitable promoter known in the art can be employed in the expression cassettes according to the present invention, including bacteria, yeasts, fungi, insects, mammals, and plant promoters. For example, plant promoters, including duckweed or microalgae promoters, can be used. Exemplary promoters include, but are not limited to, the Cauliflower Virus 35S promoter, the opine synthase promoters (e.g. nos, but, ocs, etc.), the ubiquitin promoter, the actin promoter , the ribulose biphosphate carboxylase (RubP) small subunit promoter, and the alcohol dehydrogenase promoter. The small duckweed RuBP carboxylase subunit promoter is known in the art (Silverthorne et al. (1990) Plant Mol. Biol. 15:49). Other virus promoters that infect plants or microalgae are also suitable, including, but not limited to, promoters isolated from the Dasheen mosaic virus, Chlorella virus (for example, Chlorella virus adenine methyltransferase promoter; Mitra et al. (1994 ) Plant Mol. Biol. 26:85), tomato spotted wilt virus, tobacco rattle virus, tobacco necrosis virus, tobacco ring spot virus, tomato ring spot virus, mosaic virus cucumber, peanut stump virus, alfalfa mosaic virus, sugarcane bacilliform badnavirus, and the like.
Expression control elements, including promoters, can be chosen to provide a desired level of regulation. For example, in some cases, it may be advantageous to use a promoter that confers constitutive expression (for example, the promoter of mannopine synthase of Agrobacterium tuinefadens). Alternatively, in other situations, it may be advantageous to use promoters that are activated in response to specific environmental stimuli (eg heat shock gene promoters, dry-inducible gene promoters, pathogen-inducible gene promoters, gene promoters wound-inducible, and light / dark-inducible gene promoters) or plant growth regulators (eg, gene promoters induced by abscisic acid, auxins, cytokinins, and gibberellic acid). As an additional alternative, promoters can be chosen from those that provide tissue specific expression (for example, root, leaf, and specific floral promoters).
The total strength of a given promoter can be influenced by the combination and spatial organization of cis-acting nucleotide sequences, such as upstream activation sequences. For example, nucleotide activation sequences derived from the Agrobacterium tumefaciens octopine synthase gene can enhance the transcription of the Agrobacterium tumefaciens mannopine synthase promoter (see US Patent 5,955,646). In the present invention, the expression cassette may contain nucleotide activation sequences inserted upstream of the promoter sequence to enhance the expression of the BTV antigenic polypeptide of interest, or fragment or variant thereof. In one embodiment, the expression cassette includes three upstream activation sequences derived from the Agrobacterium tumefaciens octopine synthase gene operably linked to a promoter derived from an Agrobacterium tumefaciens mannopine synthase gene (see, US Patent 5,955,646).
The expression cassette thus includes, in the 5'-3 'direction of transcription, an expression control element comprising a transcriptional and translational initiation region, a polynucleotide encoding a BTV antigenic polypeptide of interest (or fragment or variant thereof), and a functional transcriptional and translational termination region in plants. Any suitable termination sequence known in the art can be used in accordance with the present invention. The termination region can be native to the transcriptional initiation region, it can be native to the coding sequence of interest, or it can be derived from another source. Convenient termination regions are available from the Ti tumefaciens Ti plasmid, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262: 141; Proudfoot (1991) Cell 64: 671; Sanfacon et al. (1991) Genes Dev. 5: 141; Mogen et al. (1990) Plant Cell 2: 1261; Munroe et al. (1990) Gene 91: 151; Ballas et al. (1989) Nucleic Acids Res. 17: 7891; and Joshi et al. (1987) Nucleic Acids Res. 15: 9627. Additional exemplary termination sequences are the pea RubP carboxylase small subunit termination sequence and the Cauliflower Mosaic Virus 35S termination sequence.
In general, the expression cassette will comprise a selectable marker gene for the selection of transformed duckweed cells or tissues. Selectable marker genes include genes that encode antibiotic resistance, such as those that encode neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes that confer resistance to herbicidal compounds. Herbicide resistance genes usually code for a modified herbicide-insensitive target protein or an enzyme that degrades or detoxifies the herbicide in the plant before it can act. See, DeBlock et al. (1987) EMBO J. 6: 2513; DeBlock et al. (1989) Plant Physiol. 91: 691; Fromm et al. (1990) BioTechnology 8: 833; Gordon-Kamm et al. (1990) Plant Cell 2: 603. For example, resistance to glyphosate or sulfonylurea herbicides has been obtained using genes that code for mutant target enzymes, 5-enolpyruvylchiquimate-3-phosphate synthase (EPSPS) and acetolactate synthase (ALS). Resistance to ammonium glufosinate, boromoxynil, and 2,4-dichlorophenoxyacetate (2,4-D) was obtained through the use of bacterial genes that code for phosphinothricin acetyltransferase, a nitrilase, or 2,4-dichlorophenoxyacetate monooxygenase, which detoxify them respective herbicides.
For the purposes of the present invention, selectable marker genes include, but are not limited to, genes encoding neomycin phosphotransferase II (Fraley et al. (1986) CRC Critical Reviews in Plant Science 4: 1); cyanamide hydratase (Maier-Greiner et al. (1991) Proc. Natl. Acad. Sci. USA 88: 4250); aspartate kinase; dihydrodipicolinate synthase (Perl et al. (1993)
BioTechnology 11: 715); gene bar (Toki et al. (1992) Plant Physiol. 100: 1503; Meagher et al. (1996) Crop Sci. 36: 1367); tryptophan decarboxylase (Goddijn et al. (1993) Plant Mol. Biol. 22: 907); neomycin phosphotransferase (NEO; Southern et al. (1982) <J. Mol. Appl Gen. 1: 327); hygromycin phosphotransferase (HPT or HYG; Shimizu et al. (1986) Mol. Cell. Biol. 6: 1074); dihydrofolate reductase (DHFR; Kwok et al. (1986) Proc. Natl. Acad. Sci. USA 83: 4552); phosphinothricin acetyltransferase (DeBlock et al. (1987) EMBO J. 6: 2513); 2,2-dichloropropionic acid dehalogenase (Buchanan-Wollatron et al. (1989) J. Cell. Biochem. 13D: 330); acetohydroxy acid synthase (US Patent No. 4,761,373 to Anderson et al .; Haughn et al (1988) Mol. Gen. Genet. 221: 266), 5-enolpyruvyl-chiquimate-phosphate synthase (aroA; Comai et al. ( 1985)
Nature 317: 741); haloarylnitrilase (WO 87/04181 by Stalker et al.); acetylcoenzyme A carboxylase (Parker et al. (1990) Plant Physiol. 92: 1220); dihydropterate synthase (sull; Guerineau et al. (1990) Plant Mol. Biol. 15: 127); and 32 kDa photosystem II polypeptide (psbA; Hirschberg et al. (1983) Science 222: 1346 (1983).
Also included are genes encoding resistance to: gentamicin (eg, aacCl, Wohlleben et al. (1989) Mol. Gen. Genet. 217: 202-208), chloramphenicol (Herrera-Estrella et al. (1983) EMBO J 2: 987), methotrexate (Herrera-Estrella et al. (1983) Nature 303: 209; Meijer et al. (1991) Plant Mol. Biol. 16: 807); hygromycin (Waldron et al. (1985) Plant Mol. Biol. 5: 103; Zhijian et al. (1995) Plant Science 108: 219; Meijer et al. (1991) Plant Mol. Bio. 16: 807); streptomycin (Jones et al. (1987) Mol. Gen. Genet. 210: 86); spectinomycin (Bretagne-Sagnard et al. (1996) Transgenic Res. 5: 131); bleomycin (Hille et al. (1986) Plant Mol. Biol. 7: 171); sulfonamide (Guerineau et al. (1990) Plant Mol. Bio. 15: 127; bromoxynil (Stalker et al. (1988) Science 242: 419) 2,4-D (Streber et al. (1989) Biotechnology 7: 811) ; phosphinothricin (DeBlock et al. (1987) EMBO J. 6: 2513); spectinomycin (Bretagne-Sagnard and Chupeau, Transgenic Research 5: 131). The bar gene confers herbicide resistance to glufosinate-type herbicides, such as phosphinothricin ( PPT) or bialafos, and the like. As mentioned above, other selectable markers that can be used in vector constructs include, but are not limited to, the pat gene, also for resistance to bialafos and phosphinothricin, the ALS gene for imidazolinone resistance, the HPH or HYG gene for hygromycin resistance, the EPSP synthase gene for glyphosate resistance, the Hml gene for Hc-toxin resistance, and other selective agents used routinely and known to one skilled in the art. See Yarranton ( 1992) Curr. Opin. Biotech. 3: 506; Chistopherson et al. (1992) Pr oc. Natl. Acad. Sci. USA 89: 6314; Yao et al. (1992) Cell 71:63; Reznikoff (1992) Mol. Microbiol. 6: 2419; Barkley et al. (1980) The Operon 177-220; Hu et al. (1987) Cell 48: 555; Brown et al. (1987) Cell 49: 603; Figge et al. (1988) Cell 52: 713; Deuschle et al. (1989) Proc. Natl. Acad. Sci. USA 86: 5400; Fuerst et al. (1989) Proc. Natl.
Acad. Sci. USA 86: 2549; Deuschle et al. (1990) Science 248: 480; Labow et al. (1990) Mol. Cell. Biol. 10: 3343; Zambretti et al. (1992) Proc. Natl. Acad. Sci. USA 89: 3952, Baim et al. (1991) Proc. Natl. Acad. Sci. USA 88: 5072; Wyborski et al. (1991) Nuc. Acids Res. 19: 4647; Hillenand-Wissman (1989) Topics in Mol. And Struc. Biol. 10: 143; Degenkolb et al. (1991) Antimicrob. Chemother Agents. 35: 1591; Kleinschnidt et al. (1988) Biochemistry 27: 1094; Gatz et al. (1992) Plant J. 2: 397; Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89: 5547; Oliva et al. (1992) Antimicrob. Chemother Agents. 36: 913; Hlavka et al. (1985) Handbook of Experimental Pharmacology 78; and Gill et al. (1988) Nature 334: 721. Such descriptions are hereby incorporated by reference.
The above list of selectable marker genes is not intended to be limiting. Any selectable marker gene can be used in the present invention.
Modification of Nucleotide Sequences for Enhanced Expression in a Plant or Microalgae Host
When the BTV polypeptide or fragment or variant thereof is expressed within duckweed or microalgae, the expressed polynucleotide sequence encoding the BTV polypeptide or fragment or variant thereof can be modified to enhance its expression in lentil -water or micro-algae, respectively. One such modification is the synthesis of polynucleotide using preferred codons from plants, in particular the preferred codons from duckweed, or using the preferred microalgae codons, such as the preferred Schizochytrium codons. Methods are available in the art for synthesizing the nucleotide sequences with the preferred plant codons. See, for example, US Patent Nos. 5,380,831 and 5,436,391; EP 0 359 472; EP 0 385 962; WO 91/16432; Perlak et al. (1991) Proc. Natl. Acad. Sci. USA 15: 3324; lannacome et al. (1997) Plant Mol. Biol. 34: 485; and Murray et al. (1989) Nucleic Acids. Res. 17: 477. Syntheses can be performed using any method known to one skilled in the art. Preferred codons can be determined from the highest frequency codons in proteins expressed in duckweed or microalgae. For example, the frequency of codon usage for Lemna minor is found in Table A, the frequency of codon usage for Schizochytrium is found in Table B. Table A. Lemna minor [gbpln]: 4 CDS's (1597 codons)
25 Table B. Schizochytrium sp. ATCC_2088S [gbpln]: 3 CDS's (6473 codons) fields: [crack] [frequency: per thousand] ([number]) 30

For the purposes of the present invention, "codons preferred by duckweed" refer to codons that have a frequency of codon usage in duckweed greater than 17%. "Lemna-preferred codons", as used herein, refer to codons that have a frequency of codon usage in the Lemna genus greater than 17%. "Lemna minor preferred codons", as used herein, refer to codons that have a Lemna minor codon utilization frequency greater than 17%, where the Lemna minor codon utilization frequency is obtained from the Base Codon Usage Data (GenBank Release 160.0, June 15, 2007). "Preferred codons for microalgae" refer to codons that have a frequency of use of codon in microalgae greater than 17%. "Codons preferred by microalgae", as used herein, refer to codons that have a frequency of codon usage in the Thraustochytriaceae family greater than 17%. "Schizochytrium-preferred codons", as used herein, refer to codons that have a Schizochytrium codon usage frequency greater than 17%, where the frequency of Schizochytrium codon usage is obtained from the Database of Codon Use.
In addition, it is recognized that any or all of the polynucleotide encoding the BTV polypeptide of interest, or fragment or variant thereof, can be optimized or synthetic. In other words, completely optimized or partially optimized strings can also be used. For example, 40%, 45%, 50%, 55%, 60%, 6 5%, 7 0%, 7 5%, 80%, 8 5%, 87%, 90%, 91%, 92%, 93 %, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the codons can be codons preferred by microalgae or preferred by duckweed. In one embodiment, between 90 and 96% of the codons are codons preferred by microalgae or preferred by duckweed. The coding sequence of a polynucleotide sequence encoding a BTV polypeptide of interest, or fragment or variant thereof, may comprise codons used with a frequency of at least 17% in Lemna gibba or at least 17% in Lemna minor . In one embodiment, the BTV polypeptide is a VP2 or VP5 polypeptide, for example, the VP2 polypeptide as determined in SEQ ID NO: 4 or the VP5 polypeptide as determined in SEQ ID NO: 10, and the expression cassette comprises a coding sequence optimized for this VP2 polypeptide, where the coding sequence comprises codons preferred by duckweed, for example, codons preferred by Lemna minor or preferred by Lemna gibba. In such an embodiment, the expression cassette comprises SEQ ID NO: 3, which contains codons preferred by Lemna mimor that encode the VP2 polypeptide as determined in SEQ ID NO: 4. In another such embodiment, the expression cassette comprises the SEQ ID NO: 9, which contains codons preferred by Lemna minor that encode the VP5 polypeptide as determined in SEQ ID NO: 10.
Other modifications can also be made to the polynucleotide that encodes the BTV polypeptide of interest, or fragment or variant thereof, to intensify its expression in duckweed or microalgae. These modifications include, but are not limited to, the elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and others, such as well-characterized sequences that may be deleterious for gene expression . The G-C content of the sequence can be adjusted to medium levels for duckweed, as calculated by reference to the known genes expressed in this plant. When possible, the polynucleotide encoding the heterologous polypeptide of interest can be modified to avoid predicted clamp secondary mRNA structures.
There are known differences between the optimal nucleotide sequences in the context of translation initiation for translation initiation codons in animals, plants and algae. "Nucleotide sequence in the context of translation initiation" as used herein, refers to the identity of the three nucleotides directly 5 'from the translation initiation codon. "Translation initiation codon" refers to the codon that initiates the translation of the mRNA transcribed from the nucleotide sequence of interest. The composition of these nucleotide sequences in the context of translation initiation can influence the efficiency of translation initiation. See, for example, Lukaszewicz et al. (2000) Plant Science 154: 89-98; and Joshi et al. (1997); Plant Mol. Biol. 35: 993-1001. In the present invention, the nucleotide sequence in the translation initiation context for the translation initiation codon of the polynucleotide encoding the BTV antigenic polypeptide of interest, or fragment or variant thereof, can be modified to enhance duckweed expression. of water. In one embodiment, the nucleotide sequence is modified such that the three nucleotides directly upstream of the translation initiation codon are "ACC". In a second embodiment, these nucleotides are "ACA".
The expression of a BTV polypeptide in duckweed or algae can also be enhanced by the use of 5 'leader sequences. Such leader strings can act to enhance translation. Translation leaders are known in the art and include, but are not limited to, picornavirus leaders, for example, EMCV leader (Encephalomyocarditis 5 'noncoding region; Elroy-Stein et al. (1989) Proc. Natl. Acad. Sci USA 86: 6126); potivirus leaders, for example, TEV leader (Tobacco Etch Virus; Allison et al. (1986) Virology 154: 9); human heavy chain immunoglobulin binding protein (BiP;
Macajak and Sarnow (1991) Nature 353: 90); untranslated leader of the alfalfa mosaic virus coat protein (AMV RNA 4; Jobling and Gehrke (1987) Nature 325: 622); leader of the tobacco mosaic virus (TMV; Gallie (1989) Molecular Biology of RNA, 23:56); leader of the potato "etch" virus (Tomashevskaya et al (1993) J. Gen. Virol. 74: 2717-2724); Fed-15 5 'untranslated region (Dickey (1992) EMBO J. 11: 2311-2317); untranslated region RbcS 5 '(Silverthorne et al. (1990) J. Plant. Mol. Biol. 15: 49-58); and leader of the corn chlorotic mottled virus (MCMV; Lommel et al. (1991) Virology 81: 382). See also, Della-Cioppa et al. (1987) Plant Physiology 84: 965. Leader sequence comprising the plant intron sequence, including the intron sequence of the corn alcohol dehydrogenase 1 (ADH1) gene, the castor seed catalase gene, or the PAT1 gene of the Arabidopsis tryptophan pathway have also been shown to increase efficiency translation in plants (Callis et al. (1987) Genes Dev. 1: 1183-1200; Mascarenhas et al. (1990) Plant Mol. Biol. 15: 913-920).
In some embodiments of the present invention, the nucleotide sequence corresponding to nucleotides 1222-1775 of the alcohol dehydrogenase gene 1 (ADH1; GenBank accession number X04049) is inserted upstream of the polynucleotide encoding the BTV polypeptide of interest, or fragment or variant thereof, to enhance the efficiency of your translation. In another embodiment, the expression cassette contains the leader of the small subunit 5B subunit gene of Lemna gibba ribulose-bis-phosphate carboxylase (RbcS leader; see Buzby et al. (1990) Plant Cell 2: 805-814).
It is recognized that any of the expression enhancing nucleotide sequence modifications described above can be used in the present invention, including any single modification or any possible combination of modifications. The phrase "modified for enhanced expression" in duckweed, as used herein, refers to a polynucleotide sequence that contains any or any combination of these modifications.
Duckweed Plants and Transformed Duckweed Cultures or Transformed Microalgae
The present invention provides transformed duckweed plants that express a BTV polypeptide of interest, or fragment or variant thereof. The term "duckweed" refers to members of the Lemnaceae family. This family is currently divided into five genera and 38 species of duckweed, as follows: genus Lemna (L. aequinoctialis, L. disperma, L. ecuadoriensis, L. gibba, L. japonica, L. minor, L. miniscula, L. obscura, L. perpusilla, L. tenera, L. trisulca, L. turionifera, L. valdiviana); genus Spirodela (S. intermedia, S. polyrrhiza, S. punctata); genus Wolffia (Wa. angusta, Wa. arrhiza, Wa. australina, Wa. borealis, Wa. brasiliensis, Wa. columbiana, Wa. elongata, Wa. globosa, Wa. microscopic, Wa. neglecta); genus Wolfiella (Wl. caudata, Wl. denticulata, Wl. gladiata, Wl. hyalina, Wl. Ungulata, Wl. repunda, Wl. rotunda and Wl. neotropica) and genus Landoltia (L. punctata). Any other genera or species of Lemnaceae, if any, are also aspects of the present invention. Lemna species can be classified using the taxonomic scheme described by Landolt (1986) Biosystematic Investigation on the Family of Duckweeds: The family of Lemnaceae - A Monograph Study (Geobatanischen Institut ETH, Stiftung Rubel, Zurich).
As used herein, "plant" includes all plants, plant organs (e.g., fronds (leaves), stems, roots, etc.), seeds, plant cells, and offspring thereof. The parts of transgenic plants are to be understood within the scope of the invention to comprise, for example, plant cells, plant protoplasts, tissue cultures of plant cells, from which plants can be regenerated, tissues, plant calluses, embryos, as well as flowers, ova, stems, fruits, leaves, roots, root tips, nodules, and the like originating from transgenic plants or their progeny previously transformed with a polynucleotide of interest and, therefore, consisting at least of part of transgenic cells. As used herein, the term "plant cell" includes seed cells, embryos, ova, meristematic regions, callus tissues, leaves, fronds, roots, nodules, shoots, anthers, and pollen.
As used herein, "duckweed lump" means duckweed tissue comprising duckweed cells, where at least about 50%, 55%, 60%, 65%, 70 %, 75%, 80%, 85%, 90%, 95% or 100% of the cells are differentiated cells. As used herein, "differentiated cell" means a cell with at least one phenotypic characteristic (for example, a distinctive cell morphology or the expression of a marker protein or nucleic acid) that distinguishes it from non-differentiated cells or cells found in others types of fabric. The differentiated cells of the duckweed nodule culture described here form a smooth tiled surface of interconnected cells fused in their adjacent cell walls, with nodules that began to organize in the primary frond spread throughout the tissue. The surface of the nodule culture tissue has epidermal cells connected with each other through plasma desmata.
The growth pattern of duckweed is ideal for culture methods. The plant proliferates rapidly through the vegetative budding of new leaves, in a macroscopic manner analogous to asexual propagation in yeast. This proliferation occurs through vegetative budding from meristematic cells. The meristematic region is small and is located on the ventral surface of the frond. The meristematic cells rest in two pockets, one on each side of the central frond of the frond.
The small region of central rib is also the place from which the root originates and the stem appears, connecting each frond to its mother frond. The meristematic bag is protected by a fabric flap. Fronds sprout alternately from these bags. Doubling times vary according to species and are as short as 20-24 hours (Landolt (1957) Ber. Schweiz. Bot. Ges. 67: 271; Chang et al. (1977) Bull. Inst. Chera. Acad Sin. 24:19; Datko and Mudd (1970) Plant Physiol. 65:16; Venkataraman et al. (1970) Z. Pflanzenphysiol. 62: 316). Intensive duckweed cultivation results in higher biomass accumulation rates per unit of time (Landolt and Kandeler (1987) The Family of Lemnaceae - A Monographic Study Vol. 2: Phytochemistry, Physiology, Application, Bibliography (Veroffentlichungen des Geobotanischen Institutes ETH, Stiftung Rubel, Zurich)), with dry weight accumulation ranging from 6-15% of fresh weight (Tillberg et al. (1979) Physiol. Plant. 46: 5; Landolt (1957) Ber. Schweiz. Bot. Ges. 67: 271; Stomp, unpublished data). The protein content of a variety of duckweed species grown under varying conditions has been reported to range from 15-45% dry weight (Chang et al. (1977) Bull. Inst. Chem. Acad. Sin. 24 : 19; Chang and Chui (1978) Z. Pflanzenphysiol. 89:91; Porath et al. (1979) Aquatic Botany 7: 272; Appenroth et al. (1982) Biochem. Physiol. Pflanz. 177: 251). Using these values, the level of protein production per liter of duckweed medium is the same order of magnitude as the yeast gene expression systems.
The present invention also provides transformed microalgae plants that express a BTV polypeptide of interest, or fragment or variant thereof. The term "microalgae" or "microalgae" refers to members of the family Thraustochytriaceae. This family is currently divided into four genera: Schizochytrium,
Thrãustochytriumr Labyrinthuloides and Japonochytrium.
The duckweed or transformed microalgae plants of the invention can be obtained by introducing an expression construct comprising a polynucleotide encoding a BTV polypeptide, or fragment or variant thereof, in the duckweed plant. or microalgae of interest.
The term "introduction" in the context of a polynucleotide, for example, an expression construct comprising a polynucleotide encoding a BTV polypeptide, or fragment or variant thereof, is intended to mean the presentation to the duckweed plant or microalgae of the polynucleotide, in such a way that the polynucleotide gains access to the interior of a cell of the duckweed plant or microalgae. When more than one polynucleotide is to be introduced, these polynucleotides can be assembled as part of a single nucleotide construct, or as separate nucleotide constructs, and can be located on the same or different transformation vectors. Therefore, these polynucleotides can be introduced into the duckweed or microalgae host cell of interest in a single transformation event, in separate transformation events or, for example, as part of a reproduction protocol. The compositions and methods of the invention do not depend on a particular method for the introduction of one or more polynucleotides in a duckweed or microalgae plant, only that the polynucleotides gain access to the interior of at least one cell of the duckweed plant. water or microalgae. Methods for introducing polynucleotides into plants or algae are known in the art, including, but not limited to, transient transformation methods, stable transformation methods, and virus-mediated methods.
"Transient transformation" in the context of a polynucleotide, such as a polynucleotide that encodes a BTV polypeptide, or fragment or variant thereof, is intended to mean that a polynucleotide is introduced into the duckweed or microalgae plant and does not integrate into the genome of the duckweed or microalgae plant.
By "stable introduction" or "stably introduced" in the context of a polynucleotide (such as a polynucleotide encoding a BTV polypeptide, or fragment or variant thereof) introduced into a duckweed or microalgae plant if the introduced polynucleotide is stably incorporated into the duckweed or microalgae genome and, thus, the duckweed or microalgae plant is stably transformed with the polynucleotide.
"Stable transformation" or "stably transformed" means that a polynucleotide, for example, a polynucleotide that encodes a BTV polypeptide, or fragment or variant thereof, introduced into a duckweed or microalgae plant integrates into the genome of the plant or seaweed and is able to be inherited by their progeny, more particularly, by the progeny of multiple successive generations In some modalities, successive generations include offspring produced vegetatively (ie, asexual reproduction), for example, with clonal propagation. In other modalities, successive generations include offspring produced through sexual reproduction.
An expression construct comprising a polynucleotide encoding a BTV polypeptide, or fragment or variant thereof, can be introduced into a duckweed or microalgae plant of interest using any transformation protocol known to those skilled in the art. Appropriate methods for introducing nucleotide sequences into duckweed plants or plant cells or nodules or microalgae include microinjection (Crossway et al. (1986) Biotechniques 4: 320-334), electroporation (Riggs et al. (1986 ) Proc. Natl. Acad. Sci. USA 83: 5602-5606), Agrobacterium-mediated transformation (US Patent Nos. 5,563,055 and 5,981,840, both of which are incorporated by reference), direct gene transfer (Paszkowski et al. (1984 ) EMBO J. 3: 2717-2722), ballistic particle acceleration (see, for example, US Patent Nos. 4,945,050; 5,879,918; 5,886,244; and 5,932,782 (each of which is incorporated herein by reference); and Tomes et al. ( 1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile Bombardment", in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe et al. (1988) Biotechnology 6 : 923-926). The cells that have been transformed can be grown in plants according to conventional ways.
As mentioned above, stably transformed duckweed or microalgae can be obtained by any gene transfer method known in the art, such as one of the gene transfer methods described in US Patent No. 6,040,498 or US Patent Application Publications. Nos 2003/0115640, 2003/0033630 or 2002/0088027. Duckweed plants or nodule cultures or microalgae can be efficiently transformed with an expression cassette containing a nucleic acid sequence as described herein, by any of several methods, including Agrobacterium-mediated gene transfer, ballistic bombardment or electroporation. The Agrobacterium used can be Agrobacterium tumefaciens or Agrobacterium rhizogenes. The stable microalgae duckweed transformants can be isolated by transforming the duckweed or microalgae cells both with the nucleic acid sequence of interest and with a gene that confers resistance to a selection agent, followed by culture of the transformed cells in a medium containing the selection agent. See, for example, US Patent No. 6,040, 498, the contents of which are incorporated herein by reference in their entirety.
The duckweed or microalgae plants that are permanently transformed in these methods must have normal morphology and be fertile by sexual reproduction and / or capable of reproducing vegetatively (ie, asexual reproduction), for example, with clonal propagation. Preferably, the duckweed or transformed microalgae plants of the present invention contain a single copy of the transferred nucleic acid comprising a polynucleotide encoding a BTV polypeptide, or fragment or variant thereof, and the transferred nucleic acid has no rearrangements notable inside.
It is recognized that the duckweed or transformed microalgae plants of the present invention may contain the transferred nucleic acid present in low numbers of copies (that is, no more than twelve copies, no more than eight copies, no more than than five copies, alternatively, no more than three copies, as an additional alternative, less than three copies of the nucleic acid per transformed cell).
Transformed plants or microalgae expressing a BTV polypeptide, or fragment or variant thereof, can be grown under conditions suitable for the expression of the BTV antigenic polypeptide, or fragment or variant thereof. The BTV polypeptide, or fragment or variant thereof, can then be harvested from the duckweed or microalgae plant, from the culture medium, or the duckweed or microalgae plant and the culture medium and, when desired, purified using any conventional isolation and purification method known in the art, as described elsewhere in this document. The BTV antigenic polypeptide, or fragment or variant thereof, can then be formulated as a vaccine for therapeutic applications, as described elsewhere in this document. Methods of Preparation of a BTV Polypeptide
As fully described here, in one embodiment, a method of producing a BTV polypeptide comprises: (a) cultivation within a duckweed culture medium, a duckweed plant or nodule of duckweed, in which the duckweed plant or duckweed lump is stably transformed to express the polypeptide, and in which the polypeptide is expressed from a nucleotide sequence comprising a sequence coding for said polypeptide; and (b) collection of the antigenic polypeptide from the duckweed plant or duckweed nodule. The term collection includes, but is not limited to, harvesting from the culture or purification medium.
After the production of the recombinant polypeptide in duckweed or microalgae, any method available in the art can be used for protein purification. The various steps include the release of the protein from non-protein or plant or microalgae material, followed by the purification of the protein of interest from other proteins. The initial steps in the purification process include centrifugation, filtration or a combination thereof. Proteins secreted within the extracellular space of tissues can be obtained using vacuum or centrifugal extraction. Minimal processing can also involve preparing raw products. Other methods include maceration and extraction to allow the extract to be used directly.
Such methods for purifying the protein of interest can exploit differences in protein size, physicochemical properties, and binding affinity. Such methods include chromatography, including affinity for procainamide, size exclusion, high pressure liquid, reverse phase, and anion exchange chromatography, for affinity markers, filtration, etc. In particular, affinity chromatography with immobilized Ni ions can be used to purify the expressed protein. See Favacho et al. (2006) Protein Expression and Purification 46: 196-203. See also, Zhou et al. (2007) The Protein J 26: 29-37; Wang et al. (2006) Vaccine 15: 2176- 2185; and WO / 2009/076778. Protectors can be used in the purification process, such as osmotics, antioxidants, phenolic oxidation inhibitors, protease inhibitors, and the like. Methods of Use
In one embodiment, the material described herein is directed to a method of vaccinating an ovine, bovine, or caprine comprising administering to the ovine, bovine, or caprine an effective amount of a vaccine, which may comprise an effective amount of a recombinant polypeptide of BTV or antigen and a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle.
In one embodiment of the present invention, the method comprises a single administration of a vaccine composition formulated with a classic crystalline salt or emulsion according to the invention. In one embodiment, the subject described here is directed to a method of vaccination of sheep, bovine, or caprine which comprises administration to the ovine, bovine, or caprine, of the BTV polypeptide or antigen produced on a plant or seaweed, and plant material to from the genus Lemna or microalgae material from Schizochytrium.
In one embodiment, the subject described here is directed to a method for inducing an immune response which comprises administering to the sheep, bovine, or caprine a vaccine comprising the BTV polypeptide or antigen expressed on a plant or algae, in which an immune response is induced.
In one embodiment, the subject described here is directed to a method of preparing a stably transformed duckweed plant comprising, (a) introducing into the plant a genetic construct that comprises a BTV antigen gene; and (b) cultivating the plant. Methods for processing duckweed are available in the art.
In one embodiment, the subject described here is directed to a method of preparing a vaccine or composition that comprises the isolation of a BTV antigen produced by a duckweed or microalgae expression system and, optionally, combination with a pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle.
In one embodiment, the subject described here is directed to a method of preparing a vaccine or composition that comprises the combination of a BTV antigen produced by a Lemna expression system and plant material from the genus Lemna and, optionally, a carrier , excipient, adjuvant, or pharmaceutically or veterinarily acceptable vehicle.
In another embodiment, the subject described here is directed to a method of preparing a vaccine or composition comprising the combination of a BTV antigen produced by a Schízochytrium expression system and Schizochytrium material and, optionally, a carrier, excipient, adjuvant, or pharmaceutically or veterinarily acceptable vehicle.
Administration can be subcutaneous or intramuscular. The administration can be needle-free (for example, Pigjet or Bioject).
In one embodiment of the invention, a primary boosting regimen can be employed, which is composed of at least one primary boost and at least one boost boost using at least one common polypeptide, antigen, epitope, or immunogen. Typically, the immunological composition or vaccine used for primary administration is different in nature from those used as a booster. However, it is noted that the same composition can be used as the primary administration and the reinforcement. This administration protocol is called "primary reinforcement".
A primary boost according to the present invention can include a recombinant viral vector used to express a BTV coding sequence or fragments thereof. Specifically, the viral vector can express a BTV gene or fragment thereof that encodes an antigenic polypeptide. The viral vector contemplated herein includes, but is not limited to, poxvirus [for example, vaccinia virus or attenuated vaccinia virus, avipox virus or attenuated avipox virus (for example, canaripox, fowlpox, dovepox, pigeonpox, quailpox, ALVAC, TROVAC; see , for example, US 5,505,941, US 5,494,8070), raccoon pox virus, swine pox virus, etc.], adenovirus (for example, human adenovirus, canine adenovirus), herpesvirus (for example, canine herpesvirus, herpesvirus from turkey, Marek's disease virus, infectious laryngotracheitis virus, feline herpesvirus, laryngotracheitis virus (ILTV), bovine herpesvirus, swine herpesvirus), baculovirus, retrovirus, etc. In another embodiment, the avipox expression vector can be a canaripox vector, such as ALVAC. In yet another embodiment, the avipox expression vector can be a fowlpox vector, such as TROVAC. The BTV antigen of the invention to be expressed is inserted under the control of a specific poxvirus promoter, for example the Amsacta moorei entomopoxvirus 42K promoter (Barcena, Lorenzo et al. 2000), the 7.5 kDa vaccinia promoter (Cochran et al., 1985), the vaccinia I3L promoter (Riviere et al., 1992), the vaccinia HA promoter (Shida, 1986), the cowpox ATI promoter (Funahashi et al., 1988), the promoter Vaccinia H6 (Taylor et al., 1988b; Guo et al., 1989; Perkus et al., 1989), among others.
In another embodiment, the avipox expression vector can be a canaripox vector, such as ALVAC. The BTV polypeptide, antigen, epitope, or immunogen can be a BTV VP2 or BTV VP5. The viral vector can be vCP2289, which encodes synthetic VP2 and VP5 optimized for BTV codons (see, US 2007/0280960).
In another aspect of the primary booster protocol of the invention, a composition comprising the BTV antigen of the invention is administered followed by administration of the vaccine or composition comprising a recombinant viral vector that contains and expresses the BTV antigen in vivo, or a vaccine or inactivated viral composition comprising the BTV antigen, or a vaccine or DNA plasmid composition that contains or expresses the BTV antigen. Likewise, a primary booster protocol may comprise administration of a vaccine or composition comprising a recombinant viral vector that contains and expresses a BTV antigen in vivo, or a vaccine or inactivated viral composition that comprises a BTV antigen, or a vaccine or DNA plasmid composition that contains or expresses a BTV antigen, followed by administration of a composition that comprises the BTV antigen of the invention. It is further noted that both primary and secondary administrations can comprise the composition comprising the invention's BTV antigen.
The primary boost protocol comprises at least one primary boost and at least one boost boost using at least one common polypeptide and / or variants or fragments thereof. The vaccine used for primary administration may differ in nature from those used as a booster vaccine. The primary administration may comprise one or more administrations. Similarly, the booster administration may comprise one or more administrations.
The dose volume of compositions for target species that are mammals, for example, the dose volume of sheep, bovine, or goat compositions based on viral vectors, for example, compositions based on non-poxvirus viral vectors, is generally between about 0.1 to about 5.0 ml, between about 0.1 to about 3.0 ml, and between about 0.5 ml to about 2.5 ml.
The effectiveness of vaccines can be tested about 2 to 4 weeks after the last immunization by challenged animals, such as sheep, cattle, or goats, with a virulent strain of BTV, such as the BTV- 1/2/3 / strains 4/8/9/16 or 17. For example, the BTV strain can be serotype 17, which was originally isolated from the blood of sheep from Tulare County, CA (see Bonneau, DeMaula et al. 2002; DeMaula, Leutenegger and col. 2002). The BTV strain can also be serotype 8, an inactivated vaccine for which it is currently available from Merial Limited.
Other strains may include BTV1 (isolated from France), BTV1 (isolated from Australia), BTV1 (isolated from South Africa), BTV2 (isolated from the USA), BTV3 (isolated from South Africa), BTV4-9, BTV10 (isolated from the USA), BTV11 (from the USA), BTV12, BTV13 (from the USA), BTV14-17, BTV17 (from the USA), BTV18, BTV19, BTV20 (from the Australia), BTV21-24, or BTV from Corsica .
Both homologous and heterologous strains are used for the challenge of testing the vaccine's effectiveness. The animal can be challenged intradermally, subcutaneously, spray, intranasal, intraocular, intratracheal, and / or orally.
For BTV, cattle and goats are evaluated for extensive vascular injury. Also for BTV, sheep are evaluated for catarrhal inflammation of the mucous membranes of the mouth, nose and stomach, inflammation of the coronary bands and hoof blades, excoriation of the epithelium, necrosis of the oral mucosa, and swollen / inflamed / blue tongue and mouth. Smears can be collected from all animals after the challenge to isolate the virus. The presence or absence of viral antigens in the tissues indicated above can be assessed by quantitative real-time reverse transcriptase polymerase chain reaction (qRRT-PCR). Blood samples can be collected before and after the challenge and can be analyzed for the presence of specific anti-BTV antibody.
Primary reinforcement administrations can be
advantageously performed at 2 to 6 weeks apart, for example, about 3 weeks apart. According to a modality, a semi-annual boost or an annual boost, advantageously using the viral vector-based vaccine, are also provided. The animals are advantageously at least 6 to 8 weeks old at the time of the first administration.
The compositions comprising the recombinant antigenic polypeptides of the invention used in the primary reinforcement protocols are contained in a pharmaceutically or veterinarily acceptable carrier, diluent, adjuvant, or excipient. The protocols of the invention protect the animal from ovine, bovine, or caprine BTV and / or prevent disease progression in an infected animal.
The various administrations are preferably carried out 1 to 6 weeks apart and, more particularly, about 3 weeks apart. According to a preferred mode, an annual boost, preferably using the immunological composition of a viral vector-based vaccine, is also provided. The animals are preferably at least one day old at the time of the first administration.
It should be understood by one skilled in the art that the present description is provided by way of example and the present invention is not limited thereto. From the present description and knowledge in the art, the person skilled in the art can determine the number of administrations, the route of administration and the doses to be used for each injection protocol, without any excessive experimentation.
The present invention contemplates at least an administration to an animal of an effective amount of the therapeutic composition made according to the invention. The animal can be male, female, pregnant female and newborn. This administration can be through several routes, including, but not limited to, intramuscular (IM), intradermal (ID) or subcutaneous (SC) injection or through intranasal or oral administration. The therapeutic composition according to the invention can also be administered by a needle-free device (such as a Pigjet, Dermojet, Biojector, Avijet (Merial, GA, USA), Vetjet or Vitajet (Bioject, Oregon, USA) )). Another approach to administering plasmid compositions is to use electroporation (see, for example, Tollefsen et al., 2002; Tollefsen et al., 2003; Babiuk et al., 2002; PCT Application No. WO99 / 01158). In another modality, the therapeutic composition is delivered to the animal by a gene gun or gold particle bombardment.
In one embodiment, the present invention provides for the administration of a therapeutically effective amount of a formulation for the delivery and expression of a BTV antigen or epitope in a target cell. Determination of the therapeutically effective amount is routine experimentation for one skilled in the art. In one embodiment, the formulation comprises an expression vector comprising a polynucleotide that expresses a BTV antigen or epitope and a pharmaceutically or veterinarily acceptable carrier, vehicle or excipient. In another embodiment, the pharmaceutically or veterinarily acceptable carrier, vehicle or excipient facilitates transfection or other means of transferring polynucleotides to a host animal and / or improves the conservation of the vector or protein in a host.
In one embodiment, the subject described here provides a detection method for differentiating between infected and vaccinated animals (DIVA).
There are currently several BTV vaccines available. Merial offers inactivated BTV1 and BTV8 vaccines. Intervet offers inactivated BTV8 vaccines. Pfizer offers inactivated BTV1, BTV4 and BTV8 vaccines. A method for distinguishing between animals vaccinated by BTV and infected by BTV has recently been described (Anderson, J. et al., J. Virol. Methods, 1993; Silvia C. Barros et al., Veterinary-Microbiology, 2009).
It is described herein that the use of the vaccine or composition of the present invention allows the detection of BTV infection in an animal. It is described herein that the use of the vaccine or composition of the present invention allows the detection of infection in animals by differentiating between infected and vaccinated animals (DIVA). Diagnostic tests based on non-structural proteins, such as indirect NS3-ELISA and competitive ELISA using monoclonal antibody against NS1, have been developed. However, inactivated vaccines can still induce low levels of antibodies against non-structural proteins if the vaccines are not sufficiently purified. This limitation will be overcome by the present invention, expressing only the outer capsid proteins VP2 and VP5. Manufacture Article
In one embodiment, the subject described here is directed to a kit for carrying out a method of eliciting or inducing an immune response that can comprise any of the recombinant BTV immunological compositions or vaccines, or inactivated BTV immunological compositions or BTV vaccines, viral compositions or recombinant BTV vaccines, and instructions for carrying out the method.
Another embodiment of the present invention is a kit for carrying out a method of inducing an immune or protective response against BTV in an animal comprising a composition or vaccine comprising a BTV antigen of the present invention and a viral immunological composition or BTV vaccine recombinant, and instructions for performing the method of delivering an effective amount to induce an immune response in the animal.
Another embodiment of the invention is a kit for carrying out a method of inducing an immune or protective response against BTV in an animal comprising a composition or vaccine comprising a BTV antigen of the invention and an inactivated BTV immunological or BTV vaccine, and instructions for carrying out the method of delivering an effective amount to induce an immune response in the animal.
Yet another aspect of the present invention relates to a primary booster vaccination kit according to the present invention as described above. The kit can comprise at least two vials: a first vial containing a vaccine or composition for the primary vaccination according to the present invention, and a second vial containing a vaccine or composition for the booster vaccination according to the present invention. The kit may advantageously contain the first or second additional vials for additional primary vaccinations or additional booster vaccinations.
The following modalities are encompassed by the invention. In one embodiment, a composition comprising a BTV antigen or fragment or variant thereof, and a pharmaceutically or veterinarily acceptable carrier, excipient, or vehicle is described. In another embodiment, the composition described above in which the BTV antigen or fragment or variant thereof comprises an immunogenic fragment comprising at least 15 amino acids of a sheep, bovine, or goat BTV antigen is described. In yet another embodiment, the above compositions are described in which the BTV antigen or fragment or variant thereof is produced in duckweed or microalgae. In one embodiment, the above compositions are described in which the BTV antigen or fragment or variant thereof is partially purified. In one embodiment, the above compositions are described in which the BTV antigen or fragment or variant thereof is substantially purified. In one embodiment, the above compositions are described in which the BTV antigen or fragment or variant thereof is a BTV1 polypeptide. In one embodiment, the above compositions in which the BTV1 polypeptide is a VP2 or VP5 polypeptide are described. In one embodiment, the above compositions are described in which the BTV antigen or fragment or variant thereof has at least 80% sequence identity with the sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12 , 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25. In one embodiment, the above compositions are described in which the BTV antigen is encoded by a polynucleotide having at least minus 70% sequence identity to the sequence as determined in SEQ ID NO: 1, 2, 3, 5, 7, 8 or 9.
In one embodiment, the above compositions are described in which the pharmaceutically or veterinarily acceptable carrier, excipient, adjuvant, or vehicle is a water-in-oil emulsion or an oil-in-water emulsion. In another embodiment, a method of vaccinating an animal susceptible to ovine, bovine, or caprine BTV comprising administering the above compositions to the animal is described. In one embodiment, a method of vaccinating an animal susceptible to ovine, bovine, or caprine BTV comprising a primary booster regimen is described. In one embodiment, a substantially purified antigenic polypeptide expressed in duckweed or microalgae is described, wherein the polypeptide comprises: an amino acid sequence having at least 80% sequence identity to a polypeptide having the sequence as determined in SEQ ID NO: 4, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25. In any way, the animal is preferably a sheep, a bovine, or a goat. In one embodiment, a method of diagnosing BTV infection in an animal is described. In yet another embodiment, a primary booster vaccination kit is described which comprises at least two vials, wherein a first vial contains the composition of the present invention and a second vial contains a composition for the booster vaccination comprising a composition which comprises a recombinant viral vector, or a composition comprising an inactivated viral composition, or a DNA plasmid composition that contains or expresses the BTV antigen.
Pharmaceutically or veterinarily acceptable carriers, vehicles, adjuvants, or excipients are well known to one skilled in the art. For example, a pharmaceutically or veterinarily acceptable carrier, vehicle, adjuvant, or excipient can be a 0.9% NaCl solution (e.g., saline) or a phosphate buffer. Other pharmaceutically or veterinarily acceptable carriers, vehicles, adjuvants or excipients that can be used for the methods of the present invention include, but are not limited to, poly- (L-glutamate) or polyvinylpyrrolidone. Pharmaceutically or veterinarily acceptable carriers, vehicles, adjuvants or excipients can be any compound or combination of compounds that facilitate administration of the vector (or protein expressed from a vector of the invention in vitro); advantageously, the carrier, vehicle, adjuvant, or excipient can facilitate transfection and / or improve the conservation of the vector (or protein). Doses and dose volumes are discussed here in the general description and can also be determined by one skilled in the art from this description, together with knowledge in the art, without any undue experimentation. The cationic lipids containing a quaternary ammonium salt which are advantageously, but not exclusively suitable for plasmids, are advantageously those having the following formula:
where RI is a saturated or unsaturated straight chain aliphatic radical having 12 to 18 carbon atoms, R2 is another aliphatic radical containing 2 or 3 carbon atoms and X is an amine or hydroxyl group, for example, DMRIE. In another embodiment, the cationic lipid can be associated with a neutral lipid, for example, DOPE.
Among these cationic lipids, preference is given to DMRIE (N- (2-hydroxyethyl) -N, N-dimethyl-2,3-bis (tetra decyloxy) -1-propane ammonium; WO96 / 34109), advantageously associated with a lipid neutral, advantageously DOPE (dioleoyl-phosphatidyl-ethanolamine; Behr, 1994), to form DMRIE-DOPE.
Advantageously, the plasmid mixture with the adjuvant is formed extemporaneously and, advantageously, simultaneously with the administration of the preparation or immediately before the administration of the preparation; for example, just before or just before administration, the plasmid-adjuvant mixture is advantageously formed so as to provide sufficient time before administration for the mixture to form a complex, for example, between about 10 and about 60 minutes before administration, such as approximately 30 minutes before administration.
When DOPE is present, the DMRIE: DOPE molar ratio is advantageously about 95: about 5 to about 5: about 95, more advantageously about 1: about 1, for example, 1: 1.
The weight ratio of adjuvant: plasmid DMRIE or DMRIE-DOPE can be between about 50: about 1 and about 1: about 10, such as about 10: about 1 and about 1: about 5, and about 1: about 1 and about 1: about 2, for example, 1: 1 and 1: 2.
In another embodiment, the pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant may be a water-in-oil emulsion. Examples of suitable water-in-oil emulsions include oil-based water-in-oil vaccine emulsions that are stable and fluid at 4 ° C containing: from 6 to 50% v / v of an aqueous phase containing antigen, preferably from 12 to 25% v / v, 50 to 94% v / v of an oily phase containing, in whole or in part, a non-metabolizable oil (for example, mineral oil, such as paraffin oil) and / or oil metabolizable (for example, vegetable oil, or fatty acids, polyol or alcohol esters), from 0.2 to 20% w / v of surfactants, preferably from 3 to 8% w / v, the latter being in whole or in part, or in a mixture of polyglycerol esters, said polyglycerol esters preferably being polyglycerol (poly) ricinoleates, or polyoxyethylene castor oils or more hydrogenated polyoxyethylene castor oils. Examples of surfactants that can be used in a water-in-oil emulsion include ethoxylated sorbitan esters (eg, polyoxyethylene sorbitan monooleate (TWEEN 80®) (20), available from AppliChem, Inc., Cheshire, CT) and sorbitan esters (eg, sorbitan monooleate (SPAN 80®), available from Sigma Aldrich, St. Louis, MO). In addition, with respect to a water-in-oil emulsion, see also US Patent No. 6,919,084, for example, Example 8. In some embodiments, the aqueous phase containing antigen comprises a saline solution comprising one or more buffering agents. An example of a suitable buffer solution is phosphate buffered saline. In one embodiment, the water-in-oil emulsion may be a triple water / oil / water (W / O / W) emulsion (US Patent No. 6,358,500). Examples of other suitable emulsions are described in US Patent No. 7,371,395.
The immunological compositions and vaccines according to the invention can comprise or consist essentially of one or more pharmaceutically or veterinarily acceptable carriers, excipients, vehicles, or adjuvants. Suitable carriers or adjuvants for use in the practice of the present invention are (1) polymers of acrylic or methacrylic acid, maleic anhydride and polymers derived from alkenyl, (2) immunostimulation (ISS) sequences, such as oligodeoxyribonucleotide sequences having one or more non-methylated CpG units (Klinman et al., 1996; W098 / 16247), (3) an oil-in-water emulsion, such as the SPT emulsion described on page 147 of "Vaccine Design, The Subunit and Adjuvant Approach" published by M. Powell, M. Newman, Plenum Press 1995, and the MF59 emulsion described on page 183 of the same work, (4) cationic lipids containing a quaternary ammonium salt, for example, DDA (5) cytokines, (6) hydroxide aluminum or aluminum phosphate, (7) saponin or (8) other adjuvants discussed in any document cited and incorporated by reference at the time of ordering, or (9) any combinations or mixtures thereof.
The oil-in-water emulsion (3), which is especially suitable for viral vectors, can be based on: clear liquid paraffin oil (of the European pharmacopoeia type), isoprenoid oil, such as squalane, squalene, oil resulting from the oligomerization of alkenes , for example, isobutene or decene, esters of acids or alcohols that have a straight chain alkyl group, such as vegetable oils, ethyl oleate, propylene glycol, di (caprylate / caprate), glycerol tri (caprylate / caprate) and dioleate of propylene glycol, or esters of branched acids or fatty alcohols, especially esters of isostearic acid.
The oil is used in combination with emulsifiers to form an emulsion. Emulsifiers can be non-ionic surfactants, such as: sorbitan esters, mannide (eg anhydrous mannitol oleate), glycerol, polyglycerol or propylene glycol and, on the other hand, oleic, isosteric, ricinoleic or hydroxyesteric acids, said esters being optionally ethoxylated, or blocks of polyoxypropylene-polyoxyethylene copolymers, such as Pluronic, for example, L121.
Among the type (1) adjuvant polymers, preference is given to cross-linked polymers of methacrylic or acrylic acid, especially cross-linked by polyalkenyl ethers of sugars or polyalcohols. These compounds are known under the name of carbomer (Pharmeuropa, vol. 8, no. 2, June 1996). One skilled in the art can also refer to US Patent No. 2,909,462, which provides such acrylic polymers cross-linked by a polyhydroxyl compound having at least three hydroxyl groups, preferably not more than eight of such groups, the hydrogen atoms of at least three hydroxyl groups being replaced by unsaturated aliphatic radicals with at least two carbon atoms. Preferred radicals are those containing 2 to 4 carbon atoms, for example, vinyls, allyls and other ethylenically unsaturated groups. Unsaturated radicals can also contain other substituents, such as methyl. Products sold under the name Carbopol (BF Goodrich, Ohio, USA) are particularly suitable. They are cross-linked by allyl sucrose or by allyl pentaerythritol. Among them, reference is made to the Carbopol 974P, 934P and 971P.
As for copolymers derived from maleic anhydride-alkenyl, preference is given to EMA (Monsanto), which are cross-linked or straight chain copolymers of ethylene-maleic anhydride and they are, for example, cross-linked with divinyl ether. Reference is also made to J. Fields et al., 1960.
Regarding the structure, the polymers of acrylic or methacrylic acid and EMA are preferably formed by basic units with the following formula:

For EMA, x— Oey - 2e for carbomers, x = y = 1.
These polymers are soluble in water or physiological saline (20 g / 1 NaCl) and the pH can be adjusted to 7.3 to 7.4, for example, by soda (NaOH), to provide the adjuvant solution in which the expression vectors can be incorporated. The concentration of polymer in the final immunological or vaccine composition can vary between about 0.01 to about 1.5% w / v, about 0.05 to about 1% w / v, and about 0.1 about 0.4% w / v.
The cytokine or cytokines (5) can be in the form of protein in the immunological or vaccine composition, or they can be co-expressed in the host with the immunogen or their immunogens or epitopes. Preference is given to the co-expression of the cytokine or cytokines, either by the same vector, such as that which expresses the immunogen or immunogens or epitope (s) thereof, or by a separate vector thereof.
The present invention comprises the preparation of such combination compositions; for example, by mixing the active components, advantageously together and with an adjuvant, carrier, cytokine, and / or diluent.
The cytokines that can be used in the present invention include, but are not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte / macrophage colony stimulating factor (GM-CSF), interferon a (IFNα), interferon β (IFNβ), interferon y (IFN y), interleukin-lα (IL-lα), interleukin-1β (IL-lβ), interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin- 4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-9 (IL-9 ), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12), tumor necrosis factor α (TNFα), tumor necrosis factor β (TNFβ), and β transformation growth (TGFβ). It is understood that cytokines can be co-administered and / or sequentially administered with the vaccine or immunological composition of the present invention. Thus, for example, the vaccine of the present invention may also contain an exogenous nucleic acid molecule that expresses an appropriate cytokine in vivo, for example, a cytokine corresponding to that host to be vaccinated, or in which an immune response must be provoked ( for example, a bovine cytokine for preparations to be administered to cattle).
Advantageously, the immunological composition and / or vaccine according to the invention comprises or consists essentially of, or consists of an amount effective to elicit a therapeutic response to one or more polypeptides, as discussed herein; and, an effective amount can be determined from this description, including the documents incorporated herein and knowledge in the art, without undue experimentation.
In the case of the immunological composition and / or vaccine based on the expressed polypeptides, a dose can include, from about 1 pg to about 2000 pg, advantageously from about 50 pg to about 1000 pg and more advantageously from about 100 pg to about 500 pg of BTV antigen, epitope, or immunogen. The dose volumes can be between about 0.1 and about 10 ml, advantageously between about 0.2 and about 5 ml.
The invention will now be further described by means of the following non-limiting examples. EXAMPLES
The construction of inserts of DNA, plasmids and recombinant viral or plant vectors was performed using the standard molecular biology techniques described by J. Sambrook et al. (Molecular Cloning: A Laboratory Manual, second edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989).
Example 1. Construction of BTV1 VP5 expression plasmid pCG102, BTV1 VP2 expression plasmid pCG102, and BTV1 VP2 + c-Myc expression plasmid
The purpose of these experiments is to produce plasmid constructs based on pVR1012 containing the BTV serotype 1 VP2 or VP5 gene and to verify expression in transfected CHO cells. Details of pVR1012 can be found, for example, at VICAL Inc .; Luke et al., 1997; Hartikka et al., 1996; US Patents Nos. 5,846,946 and 6,451,769. These experiments were structured to produce the appropriate controls to optimize detection / quantification of BTV antigens expressed by duckweed.
BTV1 VP2 ORF optimized for mammalian expression (SEQ ID NO: 2), BTV1 VP2 optimized for mammalian expression containing c-myc tag (SEQ ID NO: 5), and BTV1 VP5 ORF optimized for mammalian expression ( SEQ ID NO: 8) were cloned into plasmid pVR1012 using the EcoRV and Xbal sites of both the vector and the insert to produce pCGlOO, pCGlOl and pCG102, respectively. In vitro expression of BTV1 VP2 protein (SEQ ID NO: 4) and BTV1 VP5 protein (SEQ ID NO: 10) was measured after transient transfection of CHO-K1 cells, using Lipofectamine 2000 (Invitrogen, Carlsbad CA). CHO-K1 at 90% confluence in 6 cm diameter plates were transfected with 5 µg of plasmid and 10 µl of Lipofectamine each, according to the manufacturer's instructions. After transfection, cells were cultured in MEM-glutamax medium (Invitrogen, Carlsbad CA), containing 1% SVF, for 24 hours. Culture supernatants were harvested and concentrated 50 times by TCA precipitation of proteins. The cells were washed with PBS, harvested by scraping and lysed using Laemmli SDS-PAGE loading buffer. The production and secretion of the recombinant protein were analyzed by submitting total cell extracts and concentrated culture supernatants (50x) to SDS-PAGE and Western blotting, both polyclonal rabbit antibody against VP2 protein (GENOVAC, Freiburg, Germany) and monoclonal antibody against VP5 protein (10AE12, Ingenasa, Spain).
The monoclonal antibody epitope used for expression analysis (AHSV10AE12 antibody supplied from Ingenasa, Spain) was mapped to amino acids 85 to 92 of the VP5 protein, a highly conserved region among the different orbiviruses, such as African Equine Disease Virus (AHSV), Blue Tongue Virus (BTV) and Epizootic Hemorrhagic Disease Virus (EHDV) (Martinez-Torrecuadrada et al. Virology, 257, 449-459; 1999). These epitope mapping results suggested that the monoclonal antibody can be used as a specific group reagent, and our results indicated that this observation was correct. The secondary antibody was anti-mouse IRDyeδOO at a dilution of 1/10000.
As shown in Figure 5, BTV1 VP5 is specifically detected in the CHO cell fraction transfected by pCG102, but not in the supernatant, by the AHSV10AE12 antibody. Figures 7 and 8 show the Western blot results for Pab L167 and Pab L168 in VP2 of different BTV serotypes. Command assignments were: 1) marker, 2) pVR1012, 3) PcglOO (VP2 BTV1), 4) pIVOOl (VP2 BTV2), 5) pIV002 (VP2 BTV4), 6) pKMR003 (VP2 BTV8), 7) pCG030 (VP2 BTV9) and 8) pIV003 (VP2 BTV 16).
Example 2. Construction of BTV duckweed expression vectors and plant transformation
BTV VP2 (SEQ ID NO: 3) and BTV VP5 (SEQ ID NO: 9) genes optimized by duckweed from the pathogenic BTV1 isolate were expressed using Biolex's LEX ™ system, a proprietary protein system Lemna minor. As shown in Figures 10, 11, 12, 13 and 14, several variants have been produced, including vectors that express both VP2 and VP5 (MerDOl and MerD02) and vectors that express only VP2 (MerD03 and MerD04).
The transgenic lines were generated for testing (Table 2). After the transgenic lines were generated, they were tested for expression of BTV in the medium and in the tissue. In summary, the plants were grown for two weeks in small research vessels and the resulting medium and tissue were collected for analysis. During tissue analysis, the frozen tissue was homogenized, centrifuged and the supernatant was removed for testing.
The extraction of crude tissue from a line containing BTV antigens was prepared. All steps were performed at 4 ° C. One hundred grams of frozen biomass (plant material harvested from the medium), were mixed with 200 ml of extraction buffer (50 mM NaPCg, 0.3 M NaCl, 10 mm EDTA, pH 7.4) and then homogenized in a Waring mixer with a blast of 20 seconds for 4 times and 10-20 seconds of cooling between them. The homogenate was centrifuged at 10,000 x g for 30 min at 4 ° C, clarified by filtration through a cellulose acetate filter (0.22 pm). The resulting homogenate was stored at 4 ° C or on ice for immediate testing. The remaining homogenate was frozen in aliquots at -80 ° C for further analysis. Total soluble protein (TSP) was determined using the Bradford assay with bovine serum albumin as a standard.
Four strains expressing BTV-1 in duckweed were selected for staging after the initial test stage. Strains that expressed high levels of VP2 were selected as the VP2 protein / antigen is considered to contribute significantly to the protective immune effect of vaccine compositions containing the said protein / antigen. The strains with the highest expression of duckweed-optimized VP2 as determined by Western blot for BTV were grown in scale vessels to provide biomass for use in animal characterization and studies. Table 2. Generation and test of duckweed cell line expressing BTV

Western blotting was used to determine the molecular weight (MW) of BTV antigens expressed in duckweed. See also US Patent Application Publication US2004 / 261148 for a detailed description of the recombinantly expressed polypeptide / duckweed antigens preparation. Briefly, 100 mg of frozen vegetable tissue was homogenized in 1 ml of extraction buffer (ratio 1:10, w / v), centrifuged and the supernatant was removed for testing. The extraction buffer was 50 mM NaPO4, 0.3 M NaCl, 10 mm EDTA, pH 7.4. TWEEN 80 1.0%, 10% glycerol, and TWEEN 80 1.0% / 10% glycerol buffers were obtained by adding appropriate amounts of TWEEN 80 and / or glycerol to the standard extraction buffer. The extracted sample was mixed in SDS buffer immediately after extraction and then followed by 2 hours of incubation on ice, followed by SDS buffer, 4 hours of incubation on ice, followed by SDS buffer, 1x, 2x, and 3x freezing - defrosting, followed by SDS buffer. The samples were then resolved on 4-20% Tris-glycine gels under reducing conditions.
It was determined that 10% glycerol should be added to the extraction buffer during VP5 protein testing. According to the data, aggregation of VP5 protein was likely and quantification using Western blot probably underestimated the amount of VP5 protein present in the sample (that is, since the protein is not well separated in the gel, residual aggregates are not detected). A VP5 monoclonal antibody clone # 10AE12 was used in Western blot for detection of VP5 expression. Western results are shown in Figure 18. The VP2 antigen was quantified using both SDS / PAGE Coomassie densitometry (Table 3) and Agilent 2100 Bioanalyzer methods (Table 4). For Coomassie densitometry, the density of the VP2 antigen bands on a Coomassie-stained standard SDS / PAGE gel was compared with a Bovine Serum Albumin (BSA) standard. Comparative densitometry then results in a concentration of VP2 protein. Quantified SDS / Coomassie densitometry results are shown in Table 3. 10 Table 3. SDS / Coomassie densitometry results

In addition to Coomassie SDS-PAGE densitometry, BTV VP2 was quantified using the Agilent 2100 Bioanalyzer. This instrument is a chip-based system designed to measure the size and quantify proteins. The measurement was performed by comparing the MW and band intensity for a standard protein scale provided by the manufacturer. The results are shown in Table 4. Table 4. Duckweed BTV1 VP2 Expression Level
1 Agilent Bioanalyzer 2100 documentation indicates 5 +/- 10% error. 2 Average Total Soluble protein was between 1.8 and 2.1 mg / ml. Based on these results, all four duckweed BTV1 strains express the VP2 antigen at a level 10 close to or above 50 pg / ml target.
Example 3. Vaccination of sheep The vaccines / formulations to be tested are shown in Table 5 below. Table 5

BTVPUR AlSapl *: Commercial BTV vaccine containing inactivated BTV1 virus. Aluminum hydroxide / Saponin1: a type of crystalline salt adjuvant. Emulsigen / CpG2: EMULSIGEN® is a commercial oil-in-water adjuvant. Thirty-one male and female sheep between 4 and 6 months of age in OD were used in the vaccination experiment. In D2, the 31 sheep were individually weighed and then randomly allocated to 5 groups of 5 sheep (GI to G5) and 1 group of 6 sheep (G6). In DO and D21, animals in the GI group received a 1 ml dose of the commercial BTVPUR AlSapl vaccine and served as positive control animals. Each animal in groups G2, G3, G4 and G5 received a dose of 1.2 ml of duckweed-BTV composition, as described in Table 6. The animals in group G6 remained untreated and served as animals of 5 negative control. Vaccine injections were performed subcutaneously on the right side of the chest next to the elbow in OD, and on the left side of the chest in D21. Table 6

BTV1 * challenge material consists of red blood cells (RBC) collected from infected sheep and stored at -70 ° C.
Example 4. Antibody titration by serum neutralization On D-29, prior to the start of the study, all sheep were negative against BTV based on ELISA titration and were thus included. His negative serological status was confirmed in OD before vaccination by SN test (serum neutralization). Average antibody titers (SN test) for each treatment group throughout the study are shown in Figure 25.
Blood tests were performed after each rectal temperature measurement. On day 0 (before the first immunization), D21 (before the second vaccination), D35, D42 (before the challenge) and D56, a blood sample in a dry tube was taken from all animals in the jugular vein. Blood samples were centrifuged to collect serum. The sera were aliquoted in two samples and then inactivated by heat (30 minutes at 56 ° C), and tested in three fold dilutions starting at 1/3 in microtiter plates. One hundred microliters of diluted serum were incubated for 1 hour at 37 ° C with 50 microtiter of a viral suspension of a given BTV serotype (BTV1) containing approximately 25 TCID50 viruses per well. Fifty microliters of a VERO cell suspension containing 500,000 cells per ml were then added to the mixture and the plates were incubated at 37 ° C for 7 days.
The reading of the plates was based on the cytopathic effect. Serum titers expressed as log (PD50%) were calculated by regression after angular transformation. A titre above 0.48 was considered to be positive.
As indicated in Figure 25, antibody titers were significantly higher than the control, before and after the challenge.
Example 5. Effectiveness of BTV vaccines produced by duckweed - Quantitative RT-PCR test
In D42 (before the challenge), D47, D49, D51, D54 and D56, all sheep had blood samples collected by jugular tube puncture. In order to detect and quantify the RNA of the Blue Tongue virus in the blood, analyzes by qRT-PCR test were performed on these samples. After RNA extraction using a commercial kit, the RNA was first denatured by heat treatment. An aliquot (in duplicate) was then incubated with a TaqMan MGB probe, specific BTV primers and reagent, according to the instructions for amplification (Invitroge Super Script III Platinum One Step Kit). The specific BTV primers were designed to hybridize the nucleic acid sequence within conserved BTV regions, conserved among all known BTV serotypes. The fluorescence signal is proportional to the amount of DNA synthesized. The quantification of BTV nucleic acids in the samples was made by comparison with standardized RNA samples. The amount of RNA was expressed as a Log10 number of copies of RNA per ml of blood.
The results of qRT-PCR are shown in Figure 26 and Table 7 below. All sheep were confirmed negative for BTV viral RNA before the challenge (D42). In G6 (control group), all sheep were positive for all analysis dates after the challenge. Titers of 10 individual viremia were elevated throughout the post-challenge period, ranging from 6.60 to 8.59 log10 RNA copies / mL. In contrast, all vaccinated animals remained negative for viremia throughout the post-challenge period. Prevention of viremia was then evidenced by 100% of the animals in each vaccinated group. The general kinetics of viremia was significantly reduced in each vaccinated group, compared to the control group (p = 0.003). Table 7. Post-challenge viremia with BTV1


Example 6, Clinical signs of BTV vaccines produced by duckweed
The rectal temperature of all animals was taken in D-2 and D-1 to accustom the animals to handling, but it was not analyzed. The injection width (in cm), number of sites and local reactions were measured using a caliper. Clinical signs were recorded in: DO (before the first immunization), DO (16:00 h), Dl, D2, D7, D14, D21 (before the second vaccination) and D21 (16:00 h), D22, D23 , D28, D35.
On day 42, the frozen challenge strain (BTV1) was thawed by partial immersion in hot water and then kept on crushed ice. All sheep were tested with 3 mL of challenge strain, injected intradermally at multiple injection points in the inguinal region. Rectal temperature measurements were performed before any other manipulations. The rectal temperatures of all animals were measured on day 42 before the test, then daily from D47 to D56. The results are shown in Figures 21, 22 and 23. As shown in Figure 23, from D47 onwards the rectal temperature in the control group (G6) increased significantly, + 0.9 ° C, on average, between D42 (challenge) and D48. In contrast, the mean rectal temperature in all vaccinated groups did not increase and remained approximately stable throughout the monitoring period. The statistical comparison showed that each vaccinated group had significantly lower maximum hyperthermia than the control group G6 (p <0.001).
From D47 to D56, a clinical examination was performed daily on all animals. Clinical signs include: congestion in the ears, eyes, nostrils, lips, swelling of the ears, eyes, snout, nostrils, lips, and canal, salivation, bleating, lameness, cough / dyspnea, diarrhea, nasal discharge / flaking, petechiae, erythema and weight. The general condition and behavior of the animals were specifically assessed on a qualitative scale: a score of 0 was assigned to "good condition", which means that the animal is perfectly healthy, mobile and attentive. A score of 1 was assigned to "apathy", which means that the animal remains distant from the others and moves slowly. A score of 2 was assigned to "depression", which means that the animal is at rest, away with the signs of attention. A score of 3 was assigned to "prostration", which means that the animal is resting in lateral and indifferent decubitus. The weight was indicated as 0 being normal, 1 being thin and 2 being malnourished. A hyperthermia score was calculated for each animal on each post-challenge day. The hyperthermia score was calculated as follows: Temp. Rectal 40.0 ° C - score of 0; 40.0 ° C <Temp. Rectal <41.0 ° C = score of 1; 41.0 ° C Temp. Rectal <42.0 ° C = score of 2; Temp. Rectal at 42.0 ° C = score of 4. A Daily Clinical Score was calculated by adding the hyperthermia score, general condition score, body condition score, number of specific clinical signs observed (+1 point per observed sign) , and number of unexpected signs judged to be related to the challenge (+ 1 point per recorded signal). For each animal, a Global Clinical Score (GCS) was calculated by adding the individual Daily Clinical Scores during the post-challenge period (D47-D56). The average Daily Clinical Score is shown in Figure 24. The result showed that in D48, the average daily clinical score in G6 (control group) peaked and remained high (between 5.8 and 6.5 points) until D51 . The GCS in this group ranged from 20 to 53 points. However, in the vaccinated groups, the mean Daily Clinical Scores remained very low (<1 point) throughout the study, and individual GCS were equal to 0 for half of the animals or never exceeded 5. The statistical comparison of GCS demonstrated a significant difference between each vaccinated group and the control group (p <0.01).
The evaluation of the effectiveness of BTV-duckweed compositions / vaccines indicated strong protection against the BTV challenge for 100% of vaccinated animals and complete prevention of viremia after challenge in all vaccinated animals. The evaluation of clinical signs showed an absence of general treatment-related reactions following vaccination, satisfactory local safety after the first and second injections, and a satisfactory immune response.
Example 7. Expression of BTV antigens in Schizochytrium
Codon-optimized BTV VP2 and VP5 genes are cloned into the expression vector pABOOlδ (ATCC deposit no. PTA9616). The nucleic acid sequence specific to the BTV gene is optimized for expression in Schizochytrium sp. In addition, the expression vector contains a selection marker cassette that confers resistance to Schizochytrium transformants, a promoter of the native Schizochytrium gene to direct expression of the transgene, and a finalizer.
Schizochytrium sp. (ATCC 20888) is used as a host for transformation with the expression vector containing the BTV gene using the electroporation method. Cryostacks of transgenic Schizochytrium strains are grown in M50-20 (described in US 2008/0022422) until confluence. The propagated Schizochytrium cultures are transferred to 50 ml conical tubes and centrifuged at 3000 g for 15 min or 100,000 g for 1 hour. The resulting pellet and the soluble fraction are used for expression analysis and in the study of animal challenge.
Having thus described in detailed preferred embodiments of the present invention, it is to be understood that the invention defined by the above paragraphs should not be limited to the particular details set out in the above description, as many apparent variations thereof are possible without departing from the spirit or scope of the present invention.
All documents cited or referenced in the documents cited in the application and all documents cited or referenced here ("documents cited here"), and all documents cited or referenced in the documents cited here, together with any instructions, descriptions, product specifications, and manufacturer's product sheets for any products mentioned herein or in any document incorporated herein by reference are hereby incorporated by reference, and may be employed in the practice of the invention.
REFERENCES Anderson, G. A., J. L. Stott, et al. (1985). "Subclinical and clinical bluetongue disease in cattle: clinical, pathological and pathogenic considerations." Prog Clin Biol Res 178: 103-7. Anderson, J., Mertens, P.P., Herniman, K.A., 1993. A competitive ELISA for the detection of anti-tubule antibodies using monoclonal antibody against bluetongue virus non-structural protein NS1. J. Virol. Methods 43, 167-175. Andreansky, S. S., B. He, et al. (1996). "The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors." Proc Natl Acad Sci USA 93 (21): 11313-8. Andrew, M., P. Whiteley, et al. (1995). "Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus." Vet Immunol Immunopathol 47 (3-4): 311-22. Antoine, G., F. Scheiflinger, et al. (1998). "The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses." Virology 244 (2): 365-96. Ballay, A., M. Levrero, et al. (1985). "In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses." Embo J 4 (13B): 3861-5. Barcena, J., M. M. Lorenzo, et al. (2000). "Sequence and analysis of a swinepox virus homologue of the vaccinia virus major envelope protein P37 (F13L)." J Gen Virol 81 (Pt 4): 1073-85. Bernard, K. A., B. A. Israel, et al. (1997). "Sequence and cognitive analyzes of two virulence-associated markers of bluetongue virus serotype 17." Intervirology 40 (4): 226-31. Bonneau, K. R., C. D. DeMaula, et al. (2002). "Duration of viremia infectious to Culicoides sonorensis in bluetongue virus-infected cattle and sheep." Vet Microbiol 88 (2): 115-25. Bonneau, K. R., B. A. Mullens, et al. (2001). "Occurrence of genetic drift and founder effect during quasispecies evolution of the VP2 and NS3 / NS3A genes of bluetongue virus upon passage between sheep, cattle, and Culicoides sonorensis." J Virol 75 (17): 8298-305. Bonneau, K. R., N. Zhang, et al. (1999). "Sequence comparison of the L2 and S10 genes of bluetongue viruses from the United States and the People's Republic of China." Virus Res 61 (2): 153-60. Boshart, M., F. Weber, et al. (1985). "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus." Cell 41 (2): 521-30. Bradel-Tretheway, B.G., Z. Zhen, et al. (2003). "Effects of codon-optimization on protein expression by the human herpesvirus 6 and 7 U51 open reading frame." J Virol Methods 111 (2): 145-56. Carroll, M. W., W. W. Overwijk, et al. (1997). "Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model." Vaccine 15 (4): 387-94. Cochran, M. A., C. Puckett, et al. (1985). "In vitro mutagenesis of the promoter region for a vaccinia virus gene: evidence for tandem early and late regulatory signals." J Virol 54 (1): 30-7. Cowley, J. A. and B. M. Gorman (1989). "Cross-neutralization of genetic reassortants of bluetongue virus serotypes 20 and 21." Vet Microbiol 19 (1): 37-51. De Groot, A. S. and F. G. Rothman (1999). "In silico predictions; in vivo veritas." Nat Biotechnol 17 (6): 533-4. de Mattos, C. A., C. C. de Mattos, et al. (1994). "Heterogeneity of the L2 gene of field isolates of bluetongue virus serotype 17 from the San Joaquin Valley of California." Virus Res 31 (1): 67-87. DeMaula, C. D., K. R. Bonneau, et al. (2000). "Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies." Virus Res 67 (1): 59-66. DeMaula, C. D., H. W. Heidner, et al. (1993). "Neutralization determinants of United States bluetongue virus serotype ten." Virology 195 (1): 292-6. DeMaula, C. D., C. M. Leutenegger, et al. (2002). "The role of endothelial cell-derived inflammatory and vasoactive mediators in the pathogenesis of bluetongue." Virology 296 (2): 330-7. Disbrow, G. L., I. Sunitha, et al. (2003). "Codon optimization of the HPV-16 E5 gene enhances protein expression." Virology 311 (1): 105-14. Feigner, J. H., R. Kumar, et al. (1994). "Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations." J Biol Chem 269 (4): 2550-61. Frolov, I., T. A. Hoffman, et al. (1996). "Alphavirus- based expression vector: strategies and applications." Proc Natl Acad Sci USA 93 (21): 11371-7. Funahashi, S., T. Sato, et al. (1988). "Cloning and characterization of the gene encoding the major protein of the A-type inclusion body of cowpox virus." J Gen Virol 69 (Pt 1): 35-47. Geysen, H. M. (1990). "Molecular technology: peptide epitope mapping and the pin technology." Southeast Asian J Trop Med Public Health 21 (4): 523-33. Geysen, H. M., S. J. Bartering, et al. (1985). "Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein." Proc Natl Acad Sci USA 82 (1): 178-82. Geysen, H. M., R. H. Meloen, et al. (1984). "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid." Proc Natl Acad Sci USA 81 (13): 3998-4002. Ghiasi, H., A. Fukusho, et al. (1987). "Identification and characterization of conserved and variable regions in the neutralization VP2 gene of bluetongue virus." Virology 160 (1): 100-9. Graham, F. L. (1990). "Adenoviruses as expression vetors and recombinant vaccines." Trends Biotechnol 8 (4): 85-7. Guo, P. X., S. Goebel, et al. (1989). "Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gpl3 and protection of immunized animals." J Virol 63 (10): 4189-98. Hartikka, J., M. Sawdey, et al. (1996). "An improved plasmid DNA expression vector for direct injection into skeletal muscle." Hum Gene Ther 7 (10): 1205-17. Hassan, S. S. and P. Roy (1999). "Expression and functional characterization of bluetongue virus VP2 protein: role in cell entry." J Virol 73 (12): 9832-42. Heidner, H. W., P. V. Rossitto, et al. (nineteen ninety). "Identification of four distinct neutralizing epitopes on bluetongue virus serotype 10 using neutralizing monoclonal antibodies and neutralization-escape variants." Virology 176 (2): 658-61. Hemmer, B., C. Pinilla, et al. (1998). "The use of soluble synthetic peptide combinatorial libraries to determine antigen recognition of T cells." J Pept Res 52 (5): 338-45. Huang, I. J., G. Y. Hwang, et al. (1995). "Sequence analyzes and antigenic epitope mapping of the putative RNA-directed RNA polymerase of five U.S. bluetongue viruses." Virology 214 (1): 280-8. Huismans, H. and B. J. Erasmus (1981). "Identification of the serotype-specific and group-specific antigens of bluetongue virus." Onderstepoort J Vet Res 48 (2): 51-8. Huismans, H., N. T. van der Walt, et al. (1987). "Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep." Virology 157 (1): 172-9. Jewell, J. E. and J. 0. Mecham (1994). "Identification of an amino acid on VP2 that affects neutralization of bluetongue virus serotype 10." Virus Res 33 (2): 139-44. Ju, Q., D. Edelstein, et al. (1998). "Transduction of non-dividing adult human pancreatic beta cells by an integrating lentiviral vector." Diabetologia 41 (6): 736-9. Kim, C. H., Y. Oh, et al. (1997). "Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells." Gene 199 (1-2): 293-301. Klinman, D. M., A. K. Yi, et al. (1996). "CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma." Proc Natl Acad Sci USA 93 (7): 2879-83. Kwissa, M., K. van Kampen, et al. (2000). "Efficient vaccination by intradermal or intramuscular inoculation of plasmid DNA expressing hepatitis B surface antigen under desmin promoter / enhancer control." Vaccine 18 (22): 2337-44. Laval, F., R. Paillot, et al. (2002). "Quantitative analysis of the antigen-specific IFNgammaJ T cell-mediated immune response in conventional outbred pigs: kinetics and duration of the DNA-induced IFNgamma + CD8 + T cell response." Vet Immunol Immunopathol 90 (3-4): 191-201. Lobato, Z. I., B. E. Coupar, et al. (1997). "Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens." Vet Immunol Immunopathoi 59 (3-4): 293-309. Luckow, V. A. and M. D. Summers (1988). "Signals important for high-level expression of foreign genes in Autographa californica nuclear polyhedrosis virus expression vectors." Virology 167 (1): 56-71. MacLachlan, N. J. (1994). "The pathogenesis and immunology of bluetongue virus infection of ruminants." Comp Immunol Microbiol Infect Dis 17 (3-4): 197-206. MacLachlan, N. J. and J. E. Pearson (2004). Bluetongue: Prodeedings of the Third International Symposium. Bluetongue: Prodeedings of the Third International Symposium. N. J. MacLachlan and J. E. Pearson, Vet Italiana. 40: 1-730. Marshall, E., L. B. Woolford, et al. (1997). "Continuous infusion of macrophage inflammatory protein MIP-lalpha enhances leukocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide." Br J Cancer 75 (12): 1715-20. Martinez-Torrecuadrada, J. L., J. P. Langeveld, et al. (1999). "Antigenic profile of African horse sickness virus serotype 4 VP5 and identification of a neutralizing epitope shared with bluetongue virus and epizootic hemorrhagic disease virus." Virology 257 (2): 449-59. McClements, W. L., M. E. Armstrong, et al. (1996). "Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease." Proc Natl Acad Sci USA 93 (21): 11414-20. Mecham, J. 0., V. C. Dean, et al. (1986). "Correlation of serotype specificity and protein structure of the five U.S. serotypes of bluetongue virus." J Gen Virol 67 (Pt 12): 2617-24. Mecham, J. 0. and D. J. Johnson (2005). "Persistence of bluetongue virus serotype 2 (BTV-2) in the southeast United States." Virus Res 113 (2): 116-22. Miyazaki, J., S. Takaki, et al. (1989). "Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5." Gene 79 (2): 269-77. Moss, B. (1996). "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety." Proc Natl Acad Sci USA 93 (21): 11341-8. Mullens, B. A., W. J. Tabachnick, et al. (1995). "Effects of temperature on virogenesis of bluetongue virus serotype 11 in Culicoides variipennis sonorensis." Med Vet Entomol 9 (1): 71-6. Paoletti, E. (1996). "Applications of pox virus vectors to vaccination: an update." Proc Natl Acad Sci USA 93 (21): 11349-53. Pearson, W. R. and D. J. Lipman (1988). "Improved tools for biological sequence comparison." Proc Natl Acad Sci EÜA 85 (8): 2444-8. Pennock, G. □., C. Shoemaker, et al. (1984). "Strong and regulated expression of Escherichia coli betagalactosidase in insect cells with a baculovirus vector." Mol Cell Biol 4 (3): 399-406. Perkus, M. E., K. Limbach, et al. (1989). "Cloning and expression of foreign genes in vaccinia virus, using a host range selection system." J Virol 63 (9): 3829-36. Powell, M. F. and M. J. Newman (1995). Vaccine Design, The Subunit and Adjuvant Approach. A Compendium of Vaccine Adjuvants and Excipients. F. Vogel and M. Powell. New York, Plenum Press. 6: 147, 183. Prevec, L., M. Schneider, et al. (1989). "Use of human adenovirus-based vectors for antigen expression in animals." J Gen Virol 70 (Pt 2): 429-34. Pritchard, L. I. and A. R. Gould (1995). "Phylogenetic comparison of the serotype-specific VP2 protein of bluetongue and related orbiviruses." Virus Res 39 (2-3): 207- Regelson, W., S. Kuhar, et al. (1960). "Synthetic polyelectrolytes as tumor inhibitors." Nature 186: 778-80- Riviere, M., J. Tartaglia, et al. (1992). "Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants." J Virol 66 (6): 3424-34. Robertson, E. S., T. Ooka, et al. (1996). "Epstein-Barr virus vectors for gene delivery to B lymphocytes." Proc Natl Acad Sci USA 93 (21): 11334-40. Robinson, H. L. and C. A. Torres (1997). "DNA vaccines." Semin Immunol 9 (5): 271-83. Roizman, B. (1996). "The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors." Proc Natl Acad Sci USA 93 (21): 11307-12. Rossitto, P. V. and N. J. MacLachlan (1992). "Neutralizing epitopes of the serotypes of bluetongue virus present in the United States." J Gen Virol 73 (Pt 8): 1947-52. Roy, P. (1992). "Bluetongue virus proteins." J Gen Virol 73 (Pt 12).-3051-64. Roy, P. (1996). "Orbivirus structure and assembly." Virology 216 (1): 1-11. Roy, P. (1996). Orbiviruses and their replication. Fields Virology. B. N. Fields, D.M. Knipe, P.M. Howley. Philadelphia, PA, Lippincott-Raven: 1709-1734. Roy, P., T. Urakawa, et al. (nineteen ninety). "Recombinant virus vaccine for bluetongue disease in sheep." J Virol 64 (5).-1998-2003. Sambrook, J. and D. W. Russell (2001). Molecular Cloning: a laboratory manual / Joseph Sambrook, David W. Russell. Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory Press. Schneider, K., F. Puehler, et al. (2000). "cDNA cloning of biologically active chicken interleukin-18." J Interferon Cytokine Res 20 (10): 879-83. Shida, H. (1986). "Nucleotide sequence of the vaccinia virus hemagglutinin gene." Virology 150 (2): 451-62. Smith, G. E., M. D. Summers, et al. (1983). "Production of human beta interferon in insect cells infected with a baculovirus expression vector." Mol Cell Biol 3 (12): 2156-65. Snedecor, G. W. and COCHRAN, W. G. (1971) Transformation of proportions in Arcsinus. In Methodes Statistiques. 6th edn. Eds H. Boelle, E. Camhaji. Association of Coordination Technique Agricole, pp 366-367. Spreull, J- (1905). "Malarial catarrhal fever (bluetongue) of sheep in South Africa." J. Comp. Path .. Ther. 18: 321-337. Stickl, H. and V. Hochstein-Mintzel (1971). "[Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (" MVA virus ")]." Munch Med Wochenschr 113 (35): 1149-53. Stittelaar, K. J., L. S. Wyatt, et al. (2000). "Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies." J Virol 74 (9): 4236-43. Sutter, G. and B. Moss (1992). "Nonreplicating vaccinia vector efficiently expresses recombinant genes." Proc Natl Acad Sci USA 89 (22): 10847-51. Sutter, G., L. S. Wyatt, et al. (1994). "A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to BTV or FMDV virus." Vaccine 12 (11): 1032-40. Tang, D. C, M. DeVit, et al. (1992). "Genetic immunization is a simple method for eliciting an immune response." Nature 356 (6365): 152-4. Taylor, J., R. Weinberg, et al. (1988). "Protective immunity against avia BTV or FMDV induced by a fowlpox virus recombinant." Vaccine 6 (6): 504-8. Thompson, J. D., D. G. Higgins, et al. (1994). "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice." Nucleic Acids Res 22 (22): 4673-80. Ulmer, J. B., J. J. Donnelly, et al. (1993). "Heterologous protection against BTV or FMDV by injection of DNA encoding a viral protein." Science 259 (5102): 1745-9. Van der Zee, R., W. Van Eden, et al. (1989). "Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides." Eur J Immunol 19 (1): 43-7. van Ooyen, A., J. van den Berg, et al. (1979). "Comparison of total sequence of a cloned rabbit beta-globin gene and its flanking regions with a homologous mouse sequence." Science 206 (4416): 337-44. Verwoerd, D. W., H. J. Els, et al. (1972). "Structure of the bluetongue virus capsid." J Virol 10 (4): 783-94. Vialard, J., M. Lalumiere, et al. (nineteen ninety). "Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the beta-galactosidase gene." J Virol 64 (1): 37-50. Wang, L. F., D. H. Du Plessis, et al. (1995). "Use of a gene-targeted phage display random epitope library to map an antigenic determinant on the bluetongue virus outer capsid protein VP5." J Immunol Methods 178 (1): 11 12. White, D. M., W. C. Wilson, et al. (2005). "Studies on overwintering of bluetongue viruses in insects. 'J Gen Virol 86 (Pt 2): 453-62. 5 Wilson, WC and J. 0. Mecham (2000)." Molecular Evolution of Orbiviruses. "Proc USAHA 104: 169 -180. Xin, KQ, K. Hamajima, et al. (1999). "IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine." Vaccine 17. (7-8): 858- 66.

权利要求:
Claims (4)
[0001]
1. Composition characterized by the fact that it comprises a BTV antigen (Lingua Azul Virus) and a carrier, excipient, adjuvant, or pharmaceutically or veterinarily acceptable carrier, in which the BTV antigen is VP2 or a combination of VP2 that has a sequence as determined in SEQ ID NO: 4 or 6 and VP5 which has a sequence as determined in SEQ ID NO: 10 of BTV serotype 1, wherein the BTV antigen is expressed in duckweed.
[0002]
2. Composition according to claim 1, characterized in that the BTV VP2 antigen is encoded by a polynucleotide as determined in SEQ ID NO: 1, 2, 3 or 5; wherein, further, the BTV VP2 antigen is encoded by a polynucleotide having the sequence as determined in SEQ ID NO: 7, 8, or 9.
[0003]
3. Use of the composition as defined in claim 1, characterized by the fact that it is for the manufacture of a vaccine for the treatment of a host susceptible to BTV.
[0004]
4. BTV antigen production process characterized by the fact that it comprises: (a) cultivating, inside a duckweed culture medium, a duckweed plant or duckweed nodule, in which the duckweed plant or duckweed lump is stably transformed to express the antigen, and wherein the antigen is expressed from a nucleotide sequence comprising a coding sequence for the antigen; and (b) collect the antigen from the duckweed plant or duckweed nodule; wherein the antigen has a sequence as determined in SEQ ID NO: 4, 6, or 10 and / or where the duckweed plant or culture comprises a plant transformation plasmid comprising a DNA fragment having the sequence as defined in SEQ ID NO: 1, 2, 3, 5, 7, 8, or 9.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112012023852B1|2020-11-10|recombinant blue tongue virus vaccines and their uses

---

US8394384B2|2013-03-12|Recombinant avian influenza vaccine and uses thereof

---

AU2016235036A1|2016-10-27|Reassortant btv and ahsv vaccines

---

US20140205619A1|2014-07-24|Recombinant avian influenza vaccine and uses thereof

---

US20140205993A1|2014-07-24|Recombinant avian influenza vaccine and uses thereof

同族专利:

---

公开号 | 公开日

---

BR112012023046B1|2020-04-07|

---

IL263249A|2020-05-31|

---

CA2792118A1|2011-09-15|

---

ZA201206619B|2013-05-29|

---

IL263253A|2020-07-30|

---

NZ702145A|2016-03-31|

---

BR112012023046A2|2017-07-18|

---

WO2011112955A1|2011-09-15|

---

EP2545067A1|2013-01-16|

---

EP3093025A1|2016-11-16|

---

CN103492410A|2014-01-01|

---

IL221781A|2018-12-31|

---

EP2944322A2|2015-11-18|

---

WO2011112945A2|2011-09-15|

---

EP3093025B1|2018-08-01|

---

EP2944322A3|2015-12-16|

---

AR080515A1|2012-04-11|

---

ES2617743T3|2017-06-19|

---

BR112012023852A2|2017-03-21|

---

WO2011112945A3|2011-11-10|

---

AU2011224188A1|2012-09-27|

---

RU2012143624A|2014-04-20|

---

CN103687614A|2014-03-26|

---

RU2575599C2|2016-02-20|

---

CA2792117A1|2011-09-15|

---

EP2544716B1|2020-01-01|

---

US20110236420A1|2011-09-29|

---

EP2545067B1|2016-11-30|

---

IL263249D0|2018-12-31|

---

EP2944322B1|2018-01-17|

---

MA34087B1|2013-03-05|

---

IL263253D0|2018-12-31|

---

CN103687614B|2018-06-08|

---

JP2013522300A|2013-06-13|

---

CA2792117C|2016-09-20|

---

ES2795148T3|2020-11-20|

---

US20110236416A1|2011-09-29|

---

NZ602278A|2014-12-24|

---

US9345759B2|2016-05-24|

---

EP2544716A2|2013-01-16|

---

US20170022255A1|2017-01-26|

---

AU2011224188B2|2015-01-22|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2909462A|1955-12-08|1959-10-20|Bristol Myers Co|Acrylic acid polymer laxative compositions|

---

US5174993A|1981-12-24|1992-12-29|Health Research Inc.|Recombinant avipox virus and immunological use thereof|

---

US4722848A|1982-12-08|1988-02-02|Health Research, Incorporated|Method for immunizing animals with synthetically modified vaccinia virus|

---

US4769330A|1981-12-24|1988-09-06|Health Research, Incorporated|Modified vaccinia virus and methods for making and using the same|

---

US5505941A|1981-12-24|1996-04-09|Health Research, Inc.|Recombinant avipox virus and method to induce an immune response|

---

US4603112A|1981-12-24|1986-07-29|Health Research, Incorporated|Modified vaccinia virus|

---

US5110587A|1981-12-24|1992-05-05|Health Research, Incorporated|Immunogenic composition comprising synthetically modified vaccinia virus|

---

EP0138854B1|1983-03-08|1992-11-04|Chiron Mimotopes Pty. Ltd.|Antigenically active amino acid sequences|

---

US4761373A|1984-03-06|1988-08-02|Molecular Genetics, Inc.|Herbicide resistance in plants|

---

EP0173552B1|1984-08-24|1991-10-09|The Upjohn Company|Recombinant dna compounds and the expression of polypeptides such as tpa|

---

US4945050A|1984-11-13|1990-07-31|Cornell Research Foundation, Inc.|Method for transporting substances into living cells and tissues and apparatus therefor|

---

US5168062A|1985-01-30|1992-12-01|University Of Iowa Research Foundation|Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence|

---

US4963481A|1985-12-18|1990-10-16|Genetics Institute Inc|Promoter system|

---

US4968615A|1985-12-18|1990-11-06|Ciba-Geigy Corporation|Deoxyribonucleic acid segment from a virus|

---

AU611080B2|1986-01-08|1991-06-06|Rhone-Poulenc Agrochimie|Haloarylnitrile degrading gene, its use, and cells containing the same|

---

US5380831A|1986-04-04|1995-01-10|Mycogen Plant Science, Inc.|Synthetic insecticidal crystal protein gene|

---

GB2197321B|1986-09-12|1990-10-03|Genentech Inc|Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line|

---

GB8717430D0|1987-07-23|1987-08-26|Celltech Ltd|Recombinant dna product|

---

DE3743138C2|1987-12-18|1990-02-22|Chr. Mayr Gmbh + Co Kg, 8951 Mauerstetten, De|

---

CA1341245C|1988-01-12|2001-06-05|F. Hoffmann-La Roche Ag|Recombinant vaccinia virus mva|

---

US5990387A|1988-06-10|1999-11-23|Pioneer Hi-Bred International, Inc.|Stable transformation of plant cells|

---

NZ230375A|1988-09-09|1991-07-26|Lubrizol Genetics Inc|Synthetic gene encoding b. thuringiensis insecticidal protein|

---

AU638438B2|1989-02-24|1993-07-01|Monsanto Technology Llc|Synthetic plant genes and method for preparation|

---

US5879918A|1989-05-12|1999-03-09|Pioneer Hi-Bred International, Inc.|Pretreatment of microprojectiles prior to using in a particle gun|

---

GB8915572D0|1989-07-07|1989-08-23|Natural Environment Res|Use of bluetongue virus proteins as vaccine components|

---

US5690938A|1989-07-07|1997-11-25|Oravax, Inc.|Oral immunization with multiple particulate antigen delivery system|

---

EP0528819A1|1990-04-18|1993-03-03|Plant Genetic Systems, N.V.|Modified bacillus thuringiensis insecticidal-crystal protein genes and their expression in plant cells|

---

US5932782A|1990-11-14|1999-08-03|Pioneer Hi-Bred International, Inc.|Plant transformation method using agrobacterium species adhered to microprojectiles|

---

KR100242671B1|1991-03-07|2000-03-02|고돈 에릭|Genetically engineered vaccine strain|

---

TW261517B|1991-11-29|1995-11-01|Mitsubishi Shozi Kk|

---

BR9306802A|1992-07-27|1998-12-08|Pioneer Hi Bred Int|Independent genotype process for the production of transgenic soybean plant and soybean plant regeneration process from cotyledon nodes|

---

AU687961B2|1993-11-19|1998-03-05|Biotechnology Research And Development Corporation|Chimeric regulatory regions and gene cassettes for expression of genes in plants|

---

CA2214029A1|1995-04-25|1996-10-31|Magda Marquet|Single-vial formulations of dna/lipid complexes|

---

US5846946A|1996-06-14|1998-12-08|Pasteur Merieux Serums Et Vaccins|Compositions and methods for administering Borrelia DNA|

---

FR2751227B1|1996-07-19|1998-11-27|Rhone Merieux|POLYNUCLEOTIDE VACCINE FORMULA AGAINST CANINE CONDITIONS, ESPECIALLY RESPIRATORY AND DIGESTIVE CONDITIONS|

---

FR2751228B1|1996-07-19|1998-11-20|Rhone Merieux|BOVINE POLYNUCLEOTIDE VACCINE FOR INTRADERMAL ROUTE|

---

FR2751226B1|1996-07-19|1998-11-27|Rhone Merieux|POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES|

---

FR2751229B1|1996-07-19|1998-11-27|Rhone Merieux|POLYNUCLEOTIDE VACCINE FORMULA IN PARTICULAR AGAINST RESPIRATORY PATHOLOGY OF CATTLE|

---

FR2751224B1|1996-07-19|1998-11-20|Rhone Merieux|POLYNUCLEOTIDE VACCINE FORMULA AGAINST BREATHING AND PIG REPRODUCTIVE CONDITIONS|

---

FR2751225B1|1996-07-19|1998-11-27|Rhone Merieux|AVIAN POLYNUCLEOTIDE VACCINE FORMULA|

---

JP4111403B2|1996-10-11|2008-07-02|ザリージェンツオブザユニバーシティーオブカリフォルニア|Immunostimulatory polynucleotide / immunomodulatory molecule complex|

---

US6045774A|1997-01-10|2000-04-04|Epicyte Pharmaceutical Inc.|J chain polypeptide targeting molecule linked to an imaging agent|

---

US5981840A|1997-01-24|1999-11-09|Pioneer Hi-Bred International, Inc.|Methods for agrobacterium-mediated transformation|

---

US8003772B2|1999-01-14|2011-08-23|Martek Biosciences Corporation|Chimeric PUFA polyketide synthase systems and uses thereof|

---

AU8444798A|1997-06-30|1999-01-25|Centre National De La Recherche Scientifique|Improved method for transferring nucleic acid into the striped muscle and combination therefor|

---

US7161064B2|1997-08-12|2007-01-09|North Carolina State University|Method for producing stably transformed duckweed using microprojectile bombardment|

---

FR2778858B1|1998-05-20|2000-06-16|Oreal|STABLE W / O / W EMULSION AND ITS USE AS A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION|

---

US6040498A|1998-08-11|2000-03-21|North Caroline State University|Genetically engineered duckweed|

---

FR2801607B1|1999-11-26|2001-12-28|Merial Sas|DUCK TIRES AND CORRESPONDING VACCINES|

---

US6852705B2|2000-01-21|2005-02-08|Merial|DNA vaccines for farm animals, in particular bovines and porcines|

---

FR2810888B1|2000-06-29|2004-07-30|Merial Sas|VACCINE AGAINST FOOT AND MOUTH DISEASE|

---

US7632983B2|2000-07-31|2009-12-15|Biolex Therapeutics, Inc.|Expression of monoclonal antibodies in duckweed|

---

CA2417415C|2000-07-31|2012-10-09|Biolex, Inc.|Expression of biologically active polypeptides in duckweed|

---

US8022270B2|2000-07-31|2011-09-20|Biolex Therapeutics, Inc.|Expression of biologically active polypeptides in duckweed|

---

US7018164B2|2000-09-06|2006-03-28|The Charles Machine Works, Inc.|Auxiliary pipe loading device|

---

TWI377253B|2001-04-16|2012-11-21|Martek Biosciences Corp|Product and process for transformation of thraustochytriales microorganisms|

---

AT453863T|2001-05-30|2010-01-15|Biolex Therapeutics Inc|USE OF THE WATER LENS FOR HIGH-THROUGH SCREENING|

---

RU2207877C1|2001-11-09|2003-07-10|Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко|Vaccine for prophylaxis and treatment of cattle, sheep and goats and deer with trichophytosis|

---

US6680200B2|2002-02-22|2004-01-20|Biolex, Inc.|Led array for illuminating cell well plates and automated rack system for handling the same|

---

NZ534881A|2002-03-19|2006-09-29|Plant Res Internat B|Mammalian GnTIII expression in plants|

---

US7176024B2|2003-05-30|2007-02-13|Biolex, Inc.|Bioreactor for growing biological materials supported on a liquid surface|

---

AT392905T|2003-07-24|2008-05-15|Merial Ltd|VACCINE FORMULATIONS WITH OIL-IN-WATER EMULSION|

---

US7527960B2|2004-06-25|2009-05-05|Merial Limited|Avipox recombinants expressing foot and mouth disease virus genes|

---

CN100582122C|2006-05-12|2010-01-20|北京宝麦德生物医药科技有限责任公司|O-type foot-and-mouth disease virus multi-epitope mucous membrane immunization vaccine and use|

---

US7862821B2|2006-06-01|2011-01-04|Merial Limited|Recombinant vaccine against bluetongue virus|

---

CN101082051A|2006-06-02|2007-12-05|广东出入境检验检疫局检验检疫技术中心|Recombined foot-and-mouth disease virus polypeptide fragment and and uses thereof|

---

CN101121938B|2007-03-23|2010-10-06|中国农业科学院兰州兽医研究所|Method for preparing foot-and-mouth disease antigen|

---

KR20100120157A|2007-11-27|2010-11-12|메디카고 인코포레이티드|Recombinant influenza virus-like particles produced in transgenic plants expressing hemagglutinin|

---

CN101970645B|2007-11-26|2018-11-30|伦敦卫生及热带医学学院|The manufacturing method of the vaccine virus strain of arc reovirus virus family viral|

---

AP3215A|2008-04-16|2015-04-30|Onderstepoort Biolog Products Ltd|Inactivated live-attenuated bluetongue virus vaccine|

---

TW201010719A|2008-08-19|2010-03-16|Wyeth Corp|Immunological composition|

---

MX2011005604A|2008-11-28|2011-09-01|Merial Ltd|Recombinant avian influenza vaccine and uses thereof.|

---

KR101939014B1|2009-03-16|2019-01-15|디에스엠 아이피 어셋츠 비.브이.|Protein production in microorganisms of the phylum Labyrinthulomycota|AU2008230795B2|2007-03-27|2014-05-29|I2 Pharmaceuticals, Inc.|Constructs and libraries comprising antibody surrogate light chain sequences|

---

WO2010132604A2|2009-05-13|2010-11-18|Sea Lane Biotechnologies, Llc|Neutralizing molecules to influenza viruses|

---

US10300140B2|2011-07-28|2019-05-28|I2 Pharmaceuticals, Inc.|Sur-binding proteins against ERBB3|

---

US9975956B2|2011-12-22|2018-05-22|I2 Pharmaceuticals, Inc.|Surrogate binding proteins which bind DR4 and/or DR5|

---

SG10201810400TA|2012-09-05|2018-12-28|Medicago Inc|Picornavirus-like particle production in plants|

---

US20140090108A1|2012-09-18|2014-03-27|Freydoun Garabagi|Vectors and Methods For Enhancing Recombinant Protein Expression in Plants|

---

EP2968519B1|2013-03-15|2020-05-06|The Trustees Of The University Of Pennsylvania|Foot and mouth disease virusconsensus proteins, coding sequences therefor and vaccines made therefrom|

---

MX365410B|2013-03-26|2019-05-31|The Pirbright Inst|Stabilised fmdv capsids.|

---

AR102006A1|2014-09-23|2017-01-25|Merial Inc|RECOMBINANT VACCINES AGAINST THE VIRUS OF AFTOSE FEVERAND ITS USES|

---

CN105624124B|2014-11-07|2020-09-29|普莱柯生物工程股份有限公司|Vaccine composition for resisting O-type foot-and-mouth disease and preparation method and application thereof|

---

US10369215B2|2015-06-02|2019-08-06|ROCA Medical Ltd.|Predilution sets for distributing antigens|

---

US10548974B2|2015-06-02|2020-02-04|ROCA Medical Ltd.|Therapeutic treatment kit for allergies based on DNA profiles|

---

WO2016202828A1|2015-06-15|2016-12-22|Bavarian Nordic A/S|Recombinant modified vaccinia virus ankarafoot and mouth disease virusvaccine|

---

MX2018006347A|2015-11-23|2019-02-20|Merial Inc|Fmdv and e2 fusion proteins and uses thereof.|

---

WO2017097875A1|2015-12-08|2017-06-15|Danmarks Tekniske Universitet|Kit-of-parts for use in a prime-boost vaccination strategy to protect cloven-footed animals against foot-and-mouth disease virus infection|

---

TWI730037B|2016-01-26|2021-06-11|日商富士軟片和光純藥股份有限公司|Photocuring method, compound and composition used therefor|

---

TW201735944A|2016-01-29|2017-10-16|梅里亞有限公司|Recombinant adenovirus vectored FMDV vaccines and uses thereof|

---

WO2017182958A1|2016-04-19|2017-10-26|Csir|Plant-produced chimaeric orbivirus vlps|

---

US10385319B2|2016-09-08|2019-08-20|The Governement of the United States of America, as represented by the Secretary of Homeland Security|Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof|

---

US10435695B2|2016-09-08|2019-10-08|The Government of the United States of America, as represented by the Secretary of Homeland Security|Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences|

---

WO2019023920A1|2017-08-01|2019-02-07|金普诺安生物科技（苏州）有限公司|Foot-and-mouth disease virus-like particle vaccine and preparation method therefor|

---

CN108273054B|2018-01-25|2020-11-17|中国农业科学院兰州兽医研究所|Porcine foot-and-mouth disease virus O-type and A-type Fc polypeptide bivalent vaccine as well as preparation method and application thereof|

---

US20210401967A1|2020-05-27|2021-12-30|The United States Of America, As Represented By The Secretary Of Agriculture|Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof|

法律状态:
2017-03-28| B15I| Others concerning applications: loss of priority|

---

2017-06-06| B12F| Appeal: other appeals|

---

2017-08-08| B25A| Requested transfer of rights approved|Owner name: BIOLEX THERAPEUTICS (US) , MERIAL, INC. (US) |

---

2019-07-09| B06T| Formal requirements before examination|

---

2019-12-31| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law|

---

2020-05-05| B09A| Decision: intention to grant|

---

2020-11-10| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2011, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

US31316410P| true| 2010-03-12|2010-03-12|

---

US61/313,164|2010-03-12|

---

US36636310P| true| 2010-07-21|2010-07-21|

---

US61/366,363|2010-07-21|

---

PCT/US2011/028131|WO2011112955A1|2010-03-12|2011-03-11|Bluetongue virus recombinant vaccines and uses thereof|

---